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I. LIST OF ABBREVATIONS 
 
7-AAD     7-aminoactinomycin D 
AA      arachidonic acid 
aPKC      atypical protein kinase C 
ASA     acetylsalicylic acid 
BSA      bovine serum albumin 
CBA      cytometric bead array 
COX      cyclooxygenase 
cPKC      conventional protein kinase C 
DTT      dithiothreitol 
ELISA     enzime linked immunosorbent assay 
EMSA     electrophoretic mobility shift assay 
FCS     fetal calf serum 
FITC     fluorescein-isothiocyanate 
GPI      glycosylphosphatidylinositol 
HRPO     horse radish peroxidase 
IL     interleukin 
IL-12R     IL-12 receptor 
IL-13Rα1    IL-13 receptor α1 
IL-4R      IL-4 receptor 
INF     interferon 
Jak     janus kinase 
LPS      lipopolysaccharide 
NK      natural killer 
nPKC      novel protein kinase C 
NSAID     non-steriod anti-inflammatory drug 
ODP      O-phenylenediamine 
PBMC      peripheral blood mononuclear cells 
PBS     phosphate buffered saline 
PE      phycoerythrin 
PG      prostaglandin 
PHA      phytohemagglutinin 
PIBF     progesterone-induced blocking factor 
PIBFR      progesterone-induced blocking factor receptor 
PI-PLC     phosphatidylinositol-specific phospholipase C 
PKC      protein kinase C 
PLA2     phopholipase A2 
PLC      phospholipase C 
PR     progesterone receptor 
Q      quinacrine 
RNAi      RNA intereference 
SCR      non-genomic sequence oligonucleotide/scrambled 
SH2     Src homology-2 domain 
SOCS      suppressor of cytokine signalling 
STAT      signal transducer and activator of transcription 
TBS      tris-buffered saline 
TCR      T cell receptor 
Th     T helper 
TNFα     tumor necrosis factor α 
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II. PROLOGUE 
 
            The fetus can be considered an allograft, since it inherits fifty per cent of its 
antigens from the father. Reproductive immunology deals with the complex regulatory 
mechanism, which enables the genetically and immunologically incompatible fetus not 
only to survive, but to develop within the potentially hostile maternal immunological 
environment for several months till delivery. Several concepts have been proposed to 
explain, how the fetus avoids being rejected by the maternal immune system, but the 
complex immuno-endocrine mechanism accounting for fetal survival is still not 
completely understood. 
            Autoimmune diseases, infections, malignant tumours show different 
symptomatology and altered epidemiology during pregnancy. In order to protect the 
mother from infectious diseases, malignancies and prevent at the same time unwanted 
immunological attack to the fetus - the immune system ensures a normal balance 
characterized by a temporary suppression of cell-mediated immune effector functions and 
a predominance of humoral immune response. 
            Successful pregnancy is a natural model of an immune regulation in a graft-host 
relationship, where the homeostasis is created by a bidirectional interaction between the 
immune and the endocrine systems. 
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III. INTRODUCTION 
 
1.       Progesterone dependent immunomodulation 
 
            Progesterone is essential for the maintenance of pregnancy in most mammalian 
species. At the beginning of pregnancy it is produced by the corpus luteum and later by 
the placenta. Progesterone modifies the activity of proteolytic enzymes, blocks the uterine 
collagenase activity (1) and inhibits the contractions of myometrial smooth muscle (2). 
High concentrations of progesterone prolong the survival of xenogenic and allogenic 
grafts (3, 4) and affects different stages of the immune response (5, 6). Progesterone was 
shown to inhibit in physiological concentrations natural cytotoxic activity of pregnancy 
lymphocytes, whereas lymphocytes of non-pregnant individuals did not respond to the 
same concentrations (7). Increased progesterone sensitivity of pregnancy lymphocytes is 
due to their higher progesterone binding capacity (8). 
            Peripheral lymphocytes of pregnant women express specific progesterone 
receptors (PRs) (9, 10, 11), which might account for the previously mentioned higher 
progesterone sensitivity of the cells. Unlike the classical PRs, lymphocyte PRs are up 
regulated by activation of the cells, and their regulation is independent from the hormonal 
environment (12). Therefore, these PRs are absent from nonpregnancy lymphocytes (9), 
but appear as early as the tenth day of gestation and disappear during term and preterm 
labour, as well as during spontaneous abortion (13).  
            A study by Chiu et al in 1996. showed, that an effective immunotherapy with 
paternal lymphocytes for unexplained recurrent spontaneous abortion resulted in increased 
PR expression on maternal lymphocytes. Since the presence of lymphocyte PRs is related 
to normal pregnancy, but their disappearance is associated with pregnancy termination, it 
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is conceivable that the lack of lymphocytic PRs during pregnancy might have functional 
consequences. 
 
1.1       Progesterone-Induced Blocking Factor 
 
            The biological effects of progesterone are manifested via a mediator protein named 
the Progesterone-Induced Blocking Factor (PIBF), which is released by lymphocytes of 
healthy pregnant women in the presence of progesterone (14). PIBF is coded on locus 
13q21-q22, which has been implicated as a common site for somatic deletions in a variety 
of malignant tumors (15) and has recently been identified in rapidly proliferating and 
undifferentiated cells, as well as in malignant tumors (16). 
            When PIBF was originally discovered, the biological functions were identified 
with a 34-36 kDa-secreted protein (14). Data from our laboratory showed that the cDNA 
of PIBF encodes a 90-kDa molecule (17). The full-length PIBF is associated with the 
centrosome (18), and the secretion of different protein forms that are synthesized due to 
alternative splicing (16), begins upon activation of the cell. 
 
PIBF has pleiotropic biological properties: 
- It interferes with arachidonic acid (AA) metabolism. 
- PIBF alters the cytokine profile. Successful pregnancy is characterized by a T helper 
(Th) 2 dominant cytokine production of peripheral lymphocytes (19) and a Th2 shifted 
cytokine pattern is thought to be important for a normal pregnancy. PIBF induces a 
significant increase in IL-10, IL-3 and IL-4 production by activated murine spleen 
cells and inhibits the IL-12 synthesis of human pregnancy lymphocytes (20). The anti-
 7
PIBF treatment of pregnant mice reduced splenic IL-10 production and resulted in 
increased NK activity together with high resorption rate (21). 
- It blocks Natural Killer (NK) cell- mediated cell lysis, and depresses the mixed 
lymphocyte reaction. 
- PIBF exerts anti-abortive effect in mice by blocking NK activity and modifying 
cytokine production (22, 23). The neutralization of endogenous PIBF or the blocking 
of progesterone binding sites by PR antagonists causes abortion in mice (24, 25, 26). 
Anti-PIBF induced pregnancy termination is associated with an increased splenic NK 
activity (8) in mice. Increased resorption rates in anti-PIBF treated mice are corrected 
by the treatment of pregnant animals with anti-NK antibody (8). These data suggest 
that – at least in mice – PIBF is indispensable for the success of pregnancy and that its 
pregnancy-protective effect is manifested via inhibiting NK activity. 
 
Although in humans there is no direct proof for a key role of PIBF in the maintenance of 
pregnancy, PIBF concentrations in sera of healthy pregnant women are higher than in 
those of non-pregnant individuals or pregnant women with sympthoms of threatened 
abortion (18). PIBF expression of the lymphocytes shows an inverse correlation with NK 
activity and the rate of PIBF positive lymphocytes is related to the outcome of pregnancy 
(14, 22). This experimental evidence implicates PIBF as a crucial factor in the 
immunomodulation during normal pregnancy. 
            The N-terminal 48-kDa part of recombinant PIBF inhibits NK activity to the same 
extent as the secreted lymphocyte PIBF does. This effect is neutralized by antibodies 
specific for the secreted PIBF. Similarly to the secreted PIBF, the recombinant molecule 
increases IL-10 production and inhibits IL-12 production by peripheral lymphocytes, both 
in a concentration dependent manner. These data suggest that the biologically active site, 
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responsible for modulating NK activity, lies within the 48-kDa N-terminal part of the 
molecule (17). 
 
1.2       Immunological effects of prostaglandins during pregnancy 
 
            Earlier observations revealed a relationship between prostaglandin (PG) levels, 
progesterone binding capacity and cytotoxic activity of lymphocytes (27).  
            PIBF maintains low NK activity via multiple mechanisms. PIBF inhibits NK cell 
cytotoxicity by increasing IL-10, and decreasing IL-12 production (28) and it inhibits 
degranulation and perforin liberation from NK cells and peripheral lymphocytes (29). PG 
output is modulated by pro-inflammatory cytokines. TNFα, IL-6 and  IL-1β activate cells 
to increase PG synthesis, but the stimulatory effect of pro-inflammatory cytokines is 
down regulated by progesterone (30). 
            Progesterone / PG imbalance (low serum concentration of progesterone with high 
serum concentration of PGs) is related to pregnancy termination (31). There is an inverse 
relationship between placental progesterone levels and PG dehydrogenase activity, 
implying that progesterone / PG balance might be regulated by inhibition of PG 
dehydrogenase by progesterone in the placenta (32). PGE2 is thought to have a mainly 
inhibitory effect on lymphocytes, whilst PGF2α stimulates lymphocyte activity (33, 34). 
According to Kuell et al. the characteristic changes in PGE2 / PGF2α ratio are strongly 
dependent on the alterations of  the progesterone / estrogen ratio during pregnancy (35).  
            The immediate precursor of PGs is AA. AA posseses a marked NK activating 
effect in vitro (36). AA is synthetized from phospholipids in the cell membrane by 
Phopholipase A2 (PLA2) or by a two step reaction catalyzed by Phospholipase C (PLC) 
and diacylglicerol lipase. The formation of PG is catalyzed by the cyclooxygenase (COX) 
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enzyme, which is located in the endoplasmatic reticulum. The transformation of AA into 
PGs involves two reactions by COX. The cyclization is the first step and it is followed by 
a peroxydase reaction. There are two main forms of COX (recent data suggest a third type 
37). COX1 is expressed constitutively and it plays a critical role in maintaining 
homeostasis, while COX2 is induced by pro-inflammatory stimuli. The inhibition of 
COX2 is responsible for the anti-inflammatory effect of non-steriod anti-inflammatory 
drugs (NSAID), whereas COX1 inhibition accounts primarily for the side effects. 
            There is a well established relationship between intrauterine infections and 
premature delivery (38, 39, 40). Bacterial endotoxins, which show elevated level in the 
amniotic fluid during intrauterine inflammation (41) by acting on COX2, stimulate PG 
synthesis. High PG levels induce myometrial contractions and at the same time exert an 
immunological effect (42, 43, 44). Increased concentrations of Th1 type cytokines are 
present during intraamniotic infection (45). Lipopolysaccharide (LPS) treatment in 
pregnant mice results in an enhanced PG synthesis and increased NK activity (46).  
            The impact of immunological effects of the COX inhibitor: Acetylsalicylic Acid 
(ASA) on the outcome of pregnancy were investigated by Szekeres et al. (33). ASA 
treatment of women showing symptoms of threatened abortion resulted in a significant 
reduction in cytotoxic activity and increased the progesterone binding capacity of  
lymphocytes remarkably. The long term administration of ASA resulted in a significantly 
lower abortion rate compared to „risk patients” receiving only traditional beta mimetic 
anti-abortive treatment (33). 
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2.    The importance of  Jak/STAT and PKC/Ca++ pathways in cytokine production   
 
            Signal transduction is a vague sort of blanket term, for what goes on inside a cell 
after a hormone, growth factor, neurotransmitter, adhesion molecule, substrate molecule 
or other signal has hit the cell membrane. There are many signalling mechanisms by 
which cells respond in a specific way to a wide variety of extracellular regulatory 
substances. 
 
2.1       STAT and SOCS signalling 
   
           The Signal Transducer and Activator of Transcription (STAT) proteins were 
identified in the last decade as transcription factors critical in mediating virtually all 
cytokine driven signalling (34). They have attracted attention because of their special 
mode of activation and the diversity of the resulting biological effects. STATs provide a 
direct link between the cytokine receptors and cytokine induced gene transcription. 
STATs are latent cytoplasmic proteins that are promptly activated by tyrosine 
phosphorylation by the cytokine receptor associated Janus kinases (Jaks). STAT 
phosphorylation allows the dimerization of individual STAT proteins via their SH2 
domains, the dimers are then capable of migrating directly to the nucleus, where they can 
bind DNA and directly activate cytokine responsive gene transcription (35).  
STATs were first identified as a unique family of DNA-binding proteins in 1993 (36) 
playing a role in interferon (INF)-regulated gene expression.  
            Following the cloning of STAT1 and STAT2, it became obvious that STAT-like 
activities were elicited by various cytokines. This prompted efforts that resulted in the 
identification of five additional mammalian STAT genes. STAT3 was cloned as an IL-6 
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activated factor by homology to STAT1. STAT4 was cloned by homology approaches; 
STAT5 was cloned as a prolactin-activated transcription factor from sheep. STAT6 was 
cloned as an IL-4-activated DNA binding factor. 
            STATs share several conserved structural and functional domains. The most 
interesting and conserved domain is a potential phosphotyrosine-binding, SRC homology 
SH2 domain (SH2). It is critical for the recruitment of STATs to activated receptor 
complexes and it is required for the interaction with the Jaks, which phosphorylate the 
STATs. Finally the SH2 domain is necessary for STAT dimerization and the associated 
ability to bind DNA (37).  
            IL-4 and IL-13 are the primary activators of STAT6. In primary B lymphocytes 
both Ig and CD40 cross-linking can induce STAT6 tyrosine phosphorylation. In the case 
of Ig cross-linking, there appears to be additional dependence on Protein Kinase C (PKC) 
to mediate this signal. The primary activation of STAT6 occurs via the ligation of the IL-4 
receptor (IL-4R).  
            The IL-4R is a heterodimer cytokine receptor system consisting of the signalling 
high-affinity α chain and a trans-activating low-affinity chain that can be either the 
common γ chain or the IL-13 receptor α1 (IL-13Rα1) chain (38). The extracellular 
domain of the IL-4Rα chain, called IL-4-binding protein, provides nearly the complete 
ligand-binding affinity of the whole receptor (39). IL-4Rα and γ chain associate with the 
Janus kinases, Jak1 and Jak3 respectively (40). Ligand-induced heterodimerization of IL-
4Rα and γ chain in lymphoid cells induces tyrosine phosphorylation of the IL-4Rα chain 
and activation of Jak1 and Jak3 (41). Phosphorylated tyrosine residues of IL-4Rα chain 
serve as anchor for the SH2 domain of STAT6, which in turn gets phosphorylated (42). 
Phosphorylated STAT6 forms homodimers that translocate to the nucleus, where they bind 
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to DNA sequences TTCNNN(N)GAA in the promoter region of IL-4 responsive genes 
(43) . 
            STAT6-deficient T helper cells are unable to differentiate into Th2 cells in vitro 
and in vivo (35). STAT6-deficient mice are markedly impaired in their ability to respond 
to IL-4. The expression of genes, known to be regulated by IL-4, such as CD23, IL-4Rα 
and MHC class II molecules, fails to increase following the IL-4 stimulation of STAT6-
deficient lymphocytes. STAT6-deficient mice do not generate an IgE response, following 
helminthic infection or immunization with the polyclonal stimulus anti-IgD. Finally the 
differentiation of Th2 cells by STAT6-deficient lymphocytes was found to be markedly 
impaired (44). 
            STAT4 plays an important role in Th1 cell function and development. STAT4 is 
mainly phosphorylated by engagement of the IL-12 receptor (IL-12R). The IL-12R is 
composed of two chains, termed IL-12Rβ1 and IL-12Rβ2. Ligand binding results in 
heterodimer formation and activation of the receptor associated Janus kinases, Jak2 and 
Tyk2. Having been phosphorylated by these tyrosine kinases, STAT4 forms homodimers 
via its SH2 domain and translocates into the nucleus, where it recognizes traditional N3 
STAT target sequences in IL-12 responsive genes. Although IL-12 appears to be the 
predominant activator of STAT4, in human cells STAT4 can also be phosphorylated in 
response to INFγ stimulation (45). 
            STAT4-deficient mice show impaired IL-12-induced responses. IL-12-induced 
INFγ production, cellular proliferation and NK cytotoxicity are all abrogated in the 
absence of STAT4. The differentiation of INFγ producing Th1 cells is markedly impaired 
in STAT4-KO mice.             
            IL-12/STAT4 and IL-4/STAT6 pathways are under negative feedback regulation 
by Suppressor of Cytokine Signalling (SOCS) Proteins (46, 47). The SOCS family of 
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proteins is composed of eight members characterized by the presence of Src homology-2 
domain (SH2) and a C-terminal conserved domain called the SOCS box. The inhibitory 
effects derive from direct interaction of SOCS SH2 domains with cytokine receptors 
and/or Jaks, leading to the recruitment of SOCS proteins to the signalling complex, to the 
inhibition of STAT binding to tyrosine-phosphorylated cytokine receptors and to the 
suppression of the catalytic activities of Jaks (48, 49, 50).  
            SOCS1 and SOCS3 genes are differentially expressed in Th1 and Th2 cells. CD4+ 
naive T cells constitutively express low levels of both SOCS1 and SOCS3 mRNAs, and 
differentiation into Th1 or Th2 phenotype is accompanied by preferential expression of 
distinct SOCS mRNA transcripts and proteins (51). Egwuagu et al. previously reported 
that Th2 cells, where IL-4/STAT6 signalling is activated and IL-12-induced STAT4 
phosphorylation is inhibited, contain 23-fold higher levels of SOCS3 than Th1 cells, in 
which 5-fold higher levels of SOCS1 are measured (51). SOCS3 is induced by IL-4 
signal, and inhibits IL-12 induced STAT4 activation by binding to the IL-12R. The 
SOCS3 SH2 domain and the docking site (shared with STAT4) in IL-12Rβ2, Tyr-800, are 
involved in this interaction (52).  
            The critical and exquisitely specific roles of STAT4 and STAT6, as well as of 
SOCS1 and SOCS3 factors in T helper cell differentiation suggest that these proteins 
would be ideal therapeutic targets for immune modulation to skew the immune response 
toward a desirable outcome. 
 
2.2       PKC and Ca++ signalling 
 
            The PKC pathway represents a major signal transduction system that is activated 
following the ligand-stimulation of receptors by hormones, neurotransmitters and growth 
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factors. PKC plays a critical role in the regulation of differentiation and proliferation in 
many cell types and in the response to diverse stimuli. 
            T cells express multiple isotypes of PKC and though it is accepted that PKCs play 
a role in T cell activation, little is known about the function of individual PKC isotypes. 
At least 11 isoenzymes have been described and classified into 3 subfamilies: Ca++ 
dependent or conventional protein kinase C (cPKC) isoforms; α, β, γ, Ca++ independent, 
novel protein kinase C (nPKC) isoforms; δ, ε, η, θ, µ or atypical phospholipase- and Ca++ 
independent protein kinase C (aPKC) isoforms ζ, ι, λ (53). 
            T cells express multiple isotypes of PKC and though it is accepted that PKCs play 
a role in T cell activation, little is known about the function of individual PKC isotypes. 
Ca++ independent PKC isoforms were involved in a PKC-induced Th2 differentiation 
(54, 55, 56) in most studies. The  loss of PKCζ leads to impairment in the secretion of Th2 
cytokines due to the  inability of the PKCζ–/– CD4+ T cells to differentiate adequately 
along the Th2 lineage, furthermore based on the currently available data, PKCζ is critical 
for IL-4 signalling and Th2 differentiation (57). According to the latest reports, PKCζ 
levels are increased during Th2 differentiation of CD4+ T cells. The lack of PKCζ impairs 
the secretion of Th2 cytokines in vitro and in vivo, as well as Jak1 activation and tyrosine 
phosphorylation. The nuclear translocation of STAT6 is inhibited in PKCζ-/- adult mice, 
they are unable to mount an optional immune response. The dramatically inhibited 
phosphorylation of STAT6 was also detected in PKCζ-/- cells and the exogenous addition 
of IL-4 could not bypass this blockade (58). 
            PKCθ is critical for the development of in vivo Th2- but not Th1 cell responses. 
PKCθ-deficient T cells exhibit impaired IL-4, but normal INFγ production (56). PKCθ-/- 
mice fail to develop Th2 cell-dependent allergic airway inflammation. The lack of IL-4 
production is consitent with the reduced level of IgE detected in in vivo models (56). 
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            Among others, the development of naive T cells into type 1 (Th1) or type 2 (Th2) 
effector cells is thought to be under the control of cytokines. IL-12 and IL-4 are widely 
accepted to be the major factors inducing T cells to develop into type 1 or type 2 direction 
(59). When IL-12 and IL-4 are present, murine and human T cell differentiation is 
regulated by the balance of PKC and Ca++ signalling within T cells (54). Th2 clones 
show reduced Ca++ flux after activation compared with Th1 clones (60). The high levels 
of PKC activity combined with low Ca++ signals favour Th2 development, while the 
predominance of Ca++ signalling with low PKC activity favours Th1 development (54). 
Signals downstream of PKC and calcineurin directly result in preferential type 1 or type 2 
cytokine gene expressions, via activation of transcription factors associated with Th2 cells 
(61, 62). 
            These mechanisms, whereby the balance of intracellular signals is induced via T 
cell receptor (TCR) stimulation, have a primary influence on the decision - a developing 
cell makes between the type 1 or type 2 pathways. 
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IV. AIMS OF THE STUDY AND RESULTS  
 
            It is well established that pregnancy is characterized by an altered cytokine balance 
induced by progesterone-dependent immunomodulation. Progesterone exerts its biological 
effects inducing Th2 shift via a regulator protein, named PIBF. The aim of this study was 
to investigate; the pathways that might be involved in mediating the cytokine effects.  
 
1. Phospholipase A 2 is involved in progesterone-dependent immunoregulation. 
 
            PIBF inhibits NK cytotoxic activity in vitro (63) and exerts an anti-abortive effect 
in vivo. PIBF also affects the cytokine secretion of peripheral lymphocytes by increasing 
IL-10 and decreasing IL-12 production (28). 
            Earlier studies revealed a relationship between PGF2α levels, progesterone 
binding capacity and cytotoxic activity of the lymphocytes (27). Par et al. observed a 
significantly increased IL-12 production in anti-PIBF treated pregnancy lymphocytes, 
which was corrected by indomethacine treatment (64).  
            It is likely that PIBF acts before the level of cyclooxygenase and lipooxygenase 
enzymes, as the blocking effect on cytotoxic activity is voided in the presence of 
exogenous AA (65). Therefore, we investigated the effect of PIBF neutralizing antibody 
and simultaneous phosholipase A2  (PLA2) inhibitor: quinacrine (Q) treatment upon IL-12 
production.  
            LPS is known to selectively stimulate PG synthesis and to enhance cytotoxicity 
(66). In our hands, LPS treatment increased the percentage of IL-12 positive cells 
significantly, and the specific cyclooxygenase inhibitor, indomethacine corrected this 
effect (67). Furthermore, Q decreased LPS induced IL-12 expression significantly, in a 
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concentration dependent manner, reaching a complete block at a concentration of 10μM.            
The treatment of lymphocytes with PIBF neutralizing antibody results in a significant 
increase of IL-12 positive mononuclear cells. We found, that IL-12 production was 
stimulated significantly, when endogenously produced PIBF was neutralized by anti-PIBF 
antibody, and the combined treatment with PLA2 inhibitor corrected anti-PIBF induced 
increased IL-12 production. The above data suggest that PIBF affects AA release. The 
subsequent block of PG synthesis reduces IL-12 production and results in a lowered NK 
activity, which favours a normal pregnancy outcome (Paper 1).  
 
2.         The effects of PIBF on STAT and SOCS signalling. 
 
            PIBF induces a Th2 biased cytokine production in vitro (28, 68) and in vivo (69). 
Activated lymphocytes produce increased amounts of Th2 type cytokines: IL-3, IL-4 and 
IL-10 in the presence of PIBF (28). The neutralization of endogenous PIBF activity results 
in an altered cytokine production and pregnancy termination in mice (70).  
            Since PIBF exerts its biological effects by inducing a Th2 bias, and the STAT 
transcription factors mediate cytokine driven signalling, we investigated the effects of 
PIBF on the STAT6/STAT4 signal transduction pathways.  
            STAT proteins are latent in the cytoplasm. Following the activation of the cell, 
they become phosphorylated and form homo- or heterodimers. These dimers enter the 
nucleus, where they bind to specific DNA elements, and in cooperation with other 
transcriptional co-activators, or transcription factors, initiate increased transcription (71). 
            To test the effect of PIBF on STAT6 phosphorylation the cytoplasmic fractions of 
PIBF-treated or untreated peripheral human lymphocytes were separated on SDS-PAGE, 
blotted to nitrocellulose membranes and reacted with anti-phospho-STAT6 antibodies. 
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Controls included isotype controls, as well as the lysate of E. coli that had undergone the 
same purification procedure as the recombinant PIBF. Similarly to IL-4, PIBF induced 
phosphorylation of STAT6, and the effect of PIBF was counteracted by neutralizing anti-
PIBF IgG (Fig.1).  
 
0 PIBF IL-4 PIBF
+
E.coli
anti
PIBF
WB: anti-phospho(Tyr-641)STAT6
WB: anti-STAT6
 
 
 
 
 
 
Fig.1 The effect of PIBF on STAT6 phosphorylation 
 
            To clarify whether PIBF induces nuclear translocation of phosphorylated STAT6 
dimers, nuclear extracts prepared from cells treated with 48-kDa N-terminal recombinant 
human PIBF, and those of IL-4 treated, as well as untreated lymphocytes were hybridized 
with radioactive labeled STAT6 binding specific oligonucleotide probes 5’ 
TCGACTTCCCAAGAACAGCA 3’ and their reverse complementary pairs. The samples 
were separated by non-denaturating PAGE and the bands were detected by 
autoradiography. PIBF induced the nuclear translocation of STAT6 proteins in 
lymphocytes. Supershift assay was performed to determine the specificity of the reaction. 
Anti-STAT6 IgG reacting with STAT6 results in the formation of STAT6/radioactive 
probe/antibody complexes, which move slower in the gel, than the smaller STAT6/probe 
complexes. PIBF treatment resulted in the nuclear translocation of STAT6. In the 
presence of an anti-STAT6 antibody, a supershifted complex appeared in the extract of 
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PIBF-treated lymphocytes. This band was not detectable, when an irrelevant antibody 
(anti-NF-κB) was used (Fig.2).  
0 IL-4 PIBF PIBF PIBF E.coli
anti - anti
STAT6 N κ B
-
F
+        +
 
 
 
 
 
 
 
Fig.2 The nuclear translocation of STAT6 dimers induced by PIBF 
 
            Next we investigated the concentration- and the time-dependent effect of PIBF. 
STAT6 phosphorylation was tested on the lysates of lymphocytes incubated with different 
concentrations of PIBF, or with 200 ng/ml of PIBF for varying periods. Tyrosine 
phosphorylated STAT6 appeared, as early as 1 min after addition of IL-4, or PIBF to the 
cells, whereas a 24 h continuous presence of progesterone was required for the same 
effect. PIBF in concentrations from 10 ng to 10 μg/ml for 5x107 cells exerted a 
concentration-dependent effect on STAT6 phosphorylation (Fig.3 ). 
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PIBF
WB: anti-phospho(Tyr-641)STAT6
WB: anti-STAT6
 
 
 
 
 
 
 
 
 
 
Fig.3 The concentration and time-dependent effects of PIBF on STAT6 induction 
 
Our earlier data show that PIBF concentrations reach 100-300 ng/ml in the urine, during 
normal pregnancy, while serum PIBF levels of the same women are usually higher. In 
patients with malignant tumors PIBF levels are more variable (100 to 1000 ng/ml in the 
urine). Based on these data, we chose 200 ng/ml for further treatments as a concentration 
relevant to in vivo biological situations.  
            Multiple mechanisms maintain low NK activity during successful pregnancy. 
PIBF inhibits NK cell cytotoxicity by increasing IL-10 and decreasing IL-12 production 
(28). Studies on STAT4 knockout mice revealed that STAT4 is necessary for the 
generation of Th1 cells and its primal activator cytokine is the IL-12 (72). To examine 
whether this effect was achieved via STAT signalling, we tested the effect of PIBF on 
STAT4 phosphorylation in the presence of IL-12. A marked STAT4 phosphorylation in 
response to IL-12 was inhibited by PIBF treatment (Fig.4).  
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WB: anti-STAT4
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+       +     IL-4R
PIBF  PIBF
+
anti-
IL4R
 
 
 
 
 
 
Fig.4 The effect of PIBF on STAT4 phosphorylation 
 
             IL-12/STAT4 and IL-4/STAT6 transcription are under negative control regulation 
by SOCSs (46, 47). Naive T cells express low levels of both SOCS1 and SOCS3 mRNAs, 
but their differentiation into Th1 or Th2 phenotypes is accompanied by preferential 
expression of distinct SOCS transcripts and proteins. Recent studies revealed, that IL-12-
induced STAT4 activation is inhibited, but IL-4/STAT6 signalling is constitutively 
activated in Th2 cells with high levels of SOCS3, but not in Th1 cells, with high SOCS1 
expression (51). IL-12 induced STAT4 inhibition is caused by the binding of SOCS3 to 
IL-12R subunit (52). 
            Next, we investigated the sensitive feedback regulation of SOCS factors on the 
PIBF induced STAT activation or inhibition. Similarly to IL-4, PIBF-treatment induced 
SOCS3 activation in the cytoplasmic fraction of lymphocytes; whereas IL-12 induced 
SOCS1 disappeared after PIBF or IL-4 treatment (Fig.5). 
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WB: anti-beta actin
 
 
 
 
 
 
 
 
 
 
Fig.5 The effect of PIBF on SOCS1 and SOCS3 activation 
 
            In order to verify the involvement of STAT6 pathway in the cytokine effects of 
PIBF, STAT6 was silenced in peripheral lymphocytes with oligonucleotides interfering 
with STAT6 mRNA (siRNA). Cells treated with the identical nucleotides in a scrambled 
non-genomic order served as controls. The efficiency of STAT6 depletion was checked 
with the densitometry on anti-STAT6 reacted Western blots of cell lysates (Fig.6). 
 
 
 
 
 
 
 
- SCR siRNA
WB: anti-STAT6
WB: anti-beta actin
- SCR   siRNA
WB: anti-STAT4
WB: anti-STAT2
WB: anti-beta actin
WB: anti-beta actin
Fig. 6 The efficiency of STAT6 knock out in lymphocytes 
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 This shows, that STAT6 was not completely silenced by this method. The relative band 
intensity (corresponding to STAT6) calculated by Scion Image was 43.86 in intact cells (-
), 49.4 in cells treated with the non-genomic sequence oligonucleotides (SCR) and 23.72 
in cells treated with the specific siRNA.  
            The lymphocytes were incubated with PIBF for 48h, and the IL-10, IFNγ as well 
as TNFα concentrations of the culture media were determined with a cytometric bead 
assay. For controlling the effect of possible LPS contamination of recombinant PIBF, 
parallel, lymphocyte samples were treated with lysates of E. coli that had undergone the 
same purification procedure as the recombinant PIBF. Compared to the controls, the 
concentrations of both TNFα (Fig.7) and IFNγ (Fig.8) were significantly increased in 
STAT6 deficient cells treated with 10 μg/ml of PIBF. PIBF increased IL-10 production of 
intact lymphocytes in a concentration-dependent manner. Similar changes were observed 
in cells treated with non-genomic sequence oligonucleotides and in STAT6 deficient cells. 
In the latter group, PIBF-induced elevation of IL-10 production was lower compared to 
SCR control; however the difference was not statistically significant (Fig.9). A pitfall of 
the RNAi method is; that - according to recent findings - non-specific effects, that include 
both the up-regulation and suppression of non-targeted genes can be observed (73), which 
could account for elevated IL-10 levels in the supernatants of cells treated with the non-
genomic sequence. Therefore SCR control might be more appropriate as a baseline than 
untreated cells. The efficiency of STAT6 depletion was also checked by reacting the 
lysates of siRNA treated cells with anti-STAT4 and anti-STAT2 antibodies. The silencing 
was specific for STAT6 (Fig.6). 
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Fig.7 The production of TNFα induced by STAT6 deficient lymphocytes 
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Fig.8 The production of INFγ induced by STAT6 deficient lymphocytes 
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Fig.9 The production of IL-10 induced by STAT6 deficient lymphocytes 
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3.         PIBF-induced STAT6 activation is mediated by the IL-4 receptor 
 
            The activation of STAT6 pathway is initiated uniquely through IL-4R, thus IL-4 
and IL-13 are known as the primary activators of STAT6. IL-4R is a heterodimer 
consisting of the high-affinity α chain and a trans-activating low-affinity chain, that can 
be either the common γ or the IL-13Rα1 chain (38). The ligand-induced 
heterodimerization of IL-4Rα and γ chain in lymphoid cells induces the tyrosine 
phosphorylation of IL-4Rα chain and the activation of Jak1 and Jak3 kinases (41). The 
phosphorylated tyrosine residues of IL-4Rα chain serve as anchors for the 
phosphorylation of STAT6 SH2 domains (42). Based on the assumption that PIBF might 
be a ligand of IL-4R, Jak- and STAT phosphorylations were tested in PIBF activated 
lymphocytes that had been pre-treated with the blocking concentrations of anti-IL-4Rα, or 
anti-IL-13R monoclonal antibodies (mAb). The blocking of IL-13R had no effect on 
PIBF-induced STAT6 phosphorylation, but the use of IL-4R mAb at a suggested 
concentration for bioactivity neutralization, abolished STAT6 induction (Fig.10). 
 
 
WB: anti-phospho(Tyr-641)STAT6
WB: anti-STAT6
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Fig.10 The blocking of IL-4Rα inhibits PIBF induced STAT6 phosphorylation 
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PIBF induced the phosphorylation of IL-4Rα-associated Jak1, and this effect was 
counteracted by anti-IL-4R mAb treatment. The activation of γ chain-associated Jak3 was 
not detectable after PIBF treatment (Fig.11). 
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Fig.11 The effect of PIBF on Jak1 and Jak3 induction 
 
Consequently, we attempted to determine, if PIBF is a ligand of IL-4R. We could not 
demonstrate PIBF binding to IL-4R by ELISA, nor did anti-IL-4R treatment prevent PIBF 
binding to its own receptor (Fig.12, Fig.13). 
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Fig.12 The PIBF binding to IL-4Rα 
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Fig.13 The prevention of PIBF binding to its own receptor by anti-IL-4Rα treatment 
 
The possibility that the PIBF antibody binds to a region within PIBF that is required for 
interaction with the IL4R, thus competing for the same site on PIBF can be ruled out, 
because in the ELISA we used a polyclonal anti-PIBF IgG which recognizes multiple 
epitopes on the PIBF molecule. Furthermore, the assay performed in a reverse order (solid 
phase bound PIBF reacted with IL-4Rα, revealed with anti-IL-4Rα) gave similar negative 
results. Earlier we showed (28) that supernatants from spleen cells activated in the 
presence of PIBF, produce more IL-4 significantly, than those in the absence of PIBF. The 
possible scenario that instead of PIBF, PIBF-induced IL-4 would bind to the IL-4R, and 
phosphorylate STAT6, can also be excluded. Already 1 min incubation with PIBF is 
sufficient to induce the phosphorylation of STAT6. This is a too short interval for gene 
induction, plus for the synthesis of IL-4. Another argument against this concept is, that  
the treatment of the cells with anti-IL-4 antibodies did not inhibit, not even reduce - the 
effect of PIBF on STAT6 phoshorylation (Paper 4).  
            Based on the above data, the hypothesis was put forward that upon the ligand 
binding of PIBF receptor (PIBFR) might form a heterodimer with the alpha chain of the 
IL-4R, and activate STAT6 pathway. The confocal microscopy analysis of phycoerythrin 
– (PE)-anti-IL-4R labeled cells (Fig. 14 b) and fluorescein-isothiocyanate – (FITC) PIBF 
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labeled cells (Fig. 14 a) revealed a co-capping of the two receptors. Fig. 14 c represents 
the merging of  Fig. 14 a. and Fig. 14 b. The co-localization of IL-4Rα and PIBFR was 
performed at 4oC (Fig.14 lower panel) and the co-capping at 37oC (Fig.14 upper panel). 
For the capping, lymphocytes were incubated with FITC-conjugated PIBF for 30 min at 
37 oC, fixed and reacted with monoclonal anti-IL-4Rα for 45 min at room temperature, 
followed by the incubation with PE-labeled rat anti-mouse IgG 2A+B or PE-labeled rat 
anti-mouse IgG1 for 30 min at room temperature. Below, in the same panel fluorescence- 
and transmission pictures are merged to show the cellular localization of the receptors. 
 
 
a
a b c 
 
 
 
 
 
 
 
 
 
Fig.14  The confocal analysis of IL-4Rα and PIBFR co-capping 
            The above findings raise the question, why does the PIBFR need the IL-4Rα for 
signalling? A plausible explanation would be that the PIBFR itself does not possess an 
intracellular domain, thus it uses that of  IL-4Rα . 
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            Several proteins are anchored to membranes via a post-translational lipid 
modification, the glycosylphosphatidylinositol (GPI) anchor. GPI-anchored proteins have 
been found in almost all tissues and cells in mammals. In spite of the fact that these 
molecules have no transmembrane or intracellular domains, ligation of these proteins by 
antibodies results in signal transduction. Their signalling capacity is due to the association 
of these molecules with putative transmembrane proteins that can signal via conventional 
mechanisms (74). 
            Testing the hypothesis that PIBFR was a GPI anchored protein, we digested the 
putative anchoring region with phosphatidylinositol-specific phospholipase C (PI-PLC). 
IL-4 was still able to activate STAT6 in PI-PLC digested cells, but PIBF failed to do so, 
suggesting that the latter was possible a GPI anchored protein, indispensable for PIBF to 
activate STAT6 (Fig.15). 
 
WB: anti-phospho(Tyr-641)STAT6
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Fig.15  PI-PLC treatment abolishes PIBF induced STAT6 induction 
 
GPI-deficiency has been shown to cause female infertility in mice (75), but to date the 
GPI-anchored protein needed for maintaining pregnancy has not been identified. Our 
earlier data show that PIBF depletion ablates murine pregnancy (70), suggesting that 
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PIBFR might be a considered candidate. The concept that both IL-4Rα and PIBFR are 
required for PIBF signalling is supported by the following: 
1) Anti-IL-4Rα does not prevent binding of PIBF to its receptor, suggesting that PIBFR 
and IL-4Rα are separate entities.  
2) Digesting the GPI anchor abolishes PIBF driven signalling, thus a GPI-ancored protein 
is required for PIBF signalling.  
3) Anti-IL-4Rα antibody inhibits PIBF-induced STAT6 phosphorylation in intact cells 
showing that PIBF can not signal via its own receptor, without the involvement of IL-
4Rα. Taken together, the GPI-ancored PIBFR, is required, but not sufficient for PIBF 
signalling. 
 
4.        The effects of PIBF on PKC and Ca++ signalling. 
 
            The development of naive T cells into type 1 or type 2 effector cells is thought to 
be under the control of cytokines. High levels of PKC activity combined with low Ca++ 
signals favour Th2 development, while predominance of Ca++ signalling with low PKC 
activity favours Th1 development (54). Signals downstream of PKC and calcineurin 
directly result in preferential type 1 or type 2 cytokine gene expression (61, 62).  
            T cells express multiple isotypes of PKC, and though it is accepted that PKCs play 
a role in T cell activation, little is known about the function of individual PKC isotypes. 
Therefore we also examined the role of different PKC isotypes in PIBF induced 
signalling.  
            Both IL-4 and PIBF treatment induced the phosphorylation of  PKCα/β II, PKCθ 
and PKCζ , without affecting intracellular Ca++ levels (Fig.16). 
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Fig.16 The effects of PIBF on PKC isotypes and intracellular Ca++ level 
 
            The Ca++ independent, novel PKC isoform PKCθ and the atypical PKC isoform 
PKCζ are involved in the induction of type 2 development (55, 56), furthermore PKCζ 
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activity is required for Jak1 phosphorylation during IL-4 signalling. In this pathway PKCζ 
phosphorylates Jak1, which in turn activates STAT6 (57). Recently published evidence 
shows that STAT6 is dramatically inhibited in PKCζ deficient cells (58). 
            Since PIBF uses the IL-4Rα chain for STAT6 signalling, we tested, whether a 
functional IL-4Rα was required for PKC activation.  
            The effect of PIBF on the phosphorylation of PKCζ, PKCθ, and PKCα/β was 
abrogated  by the pre-treatment of the cells with blocking concentrations of anti-IL-4Rα 
antibody or anti-PIBF IgG, suggesting that both PIBF and functional IL-4Rα is needed for 
PIBF-induced PKC-activation. To test if PKC phosphorylation is needed for the effects of 
PIBF on Jak1 and STAT6 induction, we blocked PKC activity by isoform specific 
monoclonal antibodies. The results show that PKCζ and PKCθ phosphorylation, but not 
that of PKC α/β  are required for PIBF-induced Jak1 and STAT6 activation (Fig.17). 
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Fig.17 The importance of PKCζ and PKCθ activation in PIBF induced Jak1 and STAT6 
phosphorylation 
 
 
            These results suggest that the following interaction of PIBF with IL-4Rα,  PKCζ 
gets phosphorylated and activates Jak1, which in turn phosphorylates STAT6. 
Intracellular Ca++ concentrations at the same time remain unchanged resulting in a Th2 
dominant immune response. 
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V.  MATERIALS AND METHODS 
 
1.         Antibodies and PIBF 
 
            The 48-kDa N-terminal recombinant human PIBF was prepared as described 
earlier (17). 
            Polyclonal anti-PIBF antibodies were generated in our laboratory by immunizing 
rabbits with the 48-kDa N-terminal recombinant human PIBF. The antibody titers were 
determined by ELISA. IgG was affinity purified on protein A columns. 
            Monoclonal anti-IL-12 antibody (R&D Systems, Europe Ltd., Abingdon, UK) and 
HRPO-labeled anti-mouse IgG (Dako, Glostrup, Denmark) were used for 
immunocytochemistry.  
            Mouse monoclonal anti-human IL-4 Rα as well as goat polyclonal anti-human IL-
13 Rα1 antibodies (both from R&D Systems Europe Ltd., Abingdon, UK) were used for 
treatment of lymphocytes.  
            Mouse IgG 2A specific Ig (Sigma-Aldrich Inc., Budapest, Hungary), rabbit IgG 
specific- and goat IgG specific antibodies (both from Dako, Glostrup, Denmark) were 
used for isotype controls. Rabbit polyclonal phospho-specific (Tyr-641) anti-human 
STAT6, rabbit polyclonal phospho-specific (Tyr-1022/ Tyr-1023) anti-human Jak1, rabbit 
polyclonal phospho-specific (Tyr-980) anti-human Jak3, rabbit polyclonal anti-human 
SOCS1, rabbit polyclonal anti-human SOCS3 antibodies (all from Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA), rabbit polyclonal phospho-specific (Tyr-693) 
anti-human STAT4 antibody (Zymed Laboratories Inc., San Francisco, CA, USA) and 
HRPO-labeled anti-rabbit IgG (Dako, Glostrup, Denmark) were used for Western blotting. 
Polyclonal rabbit anti-human STAT6, anti-human Jak1, anti-human STAT4 antibodies (all 
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from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and rabbit anti-human β actin 
(Sigma-Aldrich Inc., Budapest, Hungary) were used for controlling the loading on 
Western blots. Rabbit polyclonal phospho-specific (Thr-410/403) anti-human PKCζ, 
phospho-specific (Thr-538) anti human PKCθ, and phospho-specific (Thr-638/641) anti-
human PKCα/β II, (all from Cell Signalling Technology, Beverly, MA, USA) were used 
for blocking and detection of PKC isotypes.  
            Polyclonal rabbit anti-human STAT6 antibody recommended for gel supershift 
studies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used for EMSA 
supershift. 
            Goat polyclonal anti-human IL-4 (R&D Systems, Europe Ltd., Abingdon, UK), 
mouse monoclonal anti-human IL-4 Rα, HRPO-labeled anti-goat IgG antibody (both from 
Dako, Glostrup, Denmark), streptavidin-biotinylated HRPO complex (Amersham 
Biosciences, Little Chalfont, UK) and polyclonal biotin-conjugated anti-PIBF antibodies 
(prepared in our laboratory) were used for ELISA test. 
            Mouse monoclonal anti-human IL-4 Rα, PE-labeled rat anti-mouse IgG 2A+B 
(BD Biosciences, San Jose, CA, USA), FITC - conjugated 48-kDa N-terminal 
recombinant human PIBF (prepared in our laboratory), PE-labeled mouse anti-human 
CD45RA and PE-labeled rat anti-mouse IgG 1 (both from BD Biosciences, San Jose, CA, 
USA), were used for immunofluorescence confocal microscopy. 
            PIBF-FITC and mouse monoclonal anti-human IL-4 Rα antibodies were used for 
determining the receptor binding of PIBF by flow cytometry. 
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2.       LPS, Quinacrine and anti-PIBF treatment 
 
            Heparinized venous blood was obtained from 20 healthy pregnant women between 
the 16th and 26th week of gestation. Peripheral blood mononuclear cells (PBMC) were 
separated on a Ficoll-Paque gradient (Pharmacia, Uppsala, Sweden) and washed in RPMI 
1640 medium (Gibco BRL, Life Technologies, Paisly, Scotland).  
            LPS (prepared from second phase Shigella sonnei in this department) was diluted 
10 μg/ml in RPMI 1640 medium. Quinacrine (Sigma-Aldrich Inc., Budapest, Hungary) 
was dissolved in ethanol and further diluted in RPMI medium from 0.1 to 100 μM 
concentrations. Stock solutions were always freshly prepared before incubations. PIBF 
specific polyclonal antibody was prepared in this laboratory as described earlier (20) and 
used at a concentration of 400 μg/ml. 
One million lymphocytes were incubated for 3 hours at 37°C, 5% CO2 with the following: 
- medium (RPMI plus 10% fetal calf serum (FCS)) 
- medium containing 10 μg/ml LPS 
- medium containing LPS and 0.1, 1, 5, 10 and 100 μM quinacrine 
- medium containing 400 μg/ml anti-PIBF 
- medium containing anti-PIBF and 10 μM quinacrine 
- medium containing 10 μM quinacrine or 400 μg/ml pre-immune rabbit polyclonal IgG 
antibody 
- to study the effect of progesterone pre-treatment on LPS treated lymphocytes, cells 
were incubated with 20 μg/ml progesterone for 24 hours at 37°C, 5% CO2  prior to 
LPS incubation. 
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The toxicity of quinacrine and progesterone treatment were tested on K562 cell line and 
on lymphocytes using Trypan blue or propidium iodine staining. The viability of K562 
cells was not altered by either treatments. 
 
3.       Immunocytochemistry 
 
            Following the incubation, the cells were washed twice in RPMI 1640 medium and 
centrifuged on glass microscope slides. The slides were dried at room temperature, the 
cells were fixed for 5 min in ice cold acetone and washed in tris-buffered saline (TBS). 
All incubations were carried out at room temperature in a humid chamber. After blocking 
endogenous peroxidase activity with 1% H2O2 the cells were further incubated in TBS 
containing 1% bovine serum albumin (BSA) (Sigma-Aldrich Inc., Budapest, Hungary) for 
blocking non-specific protein binding.  
            The primary anti-IL-12 monoclonal antibody (from R&D Systems, Europe Ltd. 
Abingdon, UK) was diluted 1:50 in TBS supplemented with 0.5% BSA and the cells were 
incubated for 1 hour. The secondary HRPO-labeled anti-mouse IgG (from Dako, 
Glostrup, Denmark) were applied at a dilution of 1:100 for 30 min. The reaction was 
developed by diaminobenzidine (Sigma-Aldrich Inc., Budapest, Hungary) followed by 
silver intensification. The nuclei were counter-stained with hematoxylin and the slides 
were mounted with gelatin-glycerol. The slides were read blind and the percentage of 
positive cells was determined after counting 500 lymphocytes in the microscope at high 
power magnification. 
            Statistics: The two tailed Student’s t-test was used for statistical evaluation of the 
data. Differences were considered significant if P-value was equal or less than 0.05. 
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4.       Treatment of lymphocytes for examination of signalling pathways 
 
            Lymphocytes of healthy non-pregnant volunteers were isolated from heparinized 
venous blood on Ficoll-Paque gradient (Pharmacia, Uppsala, Sweden), and washed in 
RPMI 1640 medium (Gibco BRL, Life Technologies, Paisly, Scotland). The cells were 
treated with 1µg/ml of Phytohemagglutinin (PHA) (Sigma-Aldrich Inc., Budapest, 
Hungary) for 24 hours and then incubated at 37°C in 5% CO2 with the following: 
-  RPMI medium 1640 (control),  
- different concentrations (10ng/ml, 20ng/ml, 200ng/ml, 0,5µg/ml, 1µg/ml, 10µg//ml for 
5x10
7
 cells) of the 48-kDa N-terminal recombinant human PIBF  
-  PIBF, progesterone (Sigma-Aldrich Inc., Budapest, Hungary) or recombinant human IL-
4 (R&D Systems Europe Ltd., Abingdon, UK) (for 1, 10, 20, 30 minutes and 24 hours),  
- recombinant human IL-4 together with recombinant human IL-12 (R&D Systems 
Europe Ltd., Abingdon, UK), or with recombinant human IL-12 in the presence of 
monoclonal anti-human IL-4Rα antibody or with monoclonal anti-human IL-4Rα 
antibody. 
- 48-kDa N-terminal recombinant human PIBF and polyclonal anti-PIBF antibody, or 
monoclonal anti-human IL-4Rα antibody, or recombinant human IL-12 together with 
monoclonal anti-human IL-4Rα antibody, or recombinant human IL-12 together with 
monoclonal anti-human IL-13Rα1 antibody   
- recombinant human IL-12 and 48-kDa N-terminal recombinant human PIBF, or 
recombinant human IL-4 
- recombinant human PIBF together with phospho-specific anti-human PKCζ, or with 
phospho-specific PKCθ, or with phospho-specific anti-human PKCα/β II. 
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- recombinant human IL-4 together with phospho-specific anti-human PKCζ, or with 
phospho-specific  PKCθ, or with phospho-specific anti-human PKCα/β II.  
- lysate of E. coli that had undergone the same purification procedure as the recombinant 
human PIBF in a concentration of 200ng/ml for 5x10
7
 cells. 
 
The phospho-specific PKC antibodies were diluted 1:100 for the treatments in blocking 
concentrations. To determine the specificity of the reactions, isotype controls were used 
with each treatment. The cytokines were used at a concentration of 200ng/ml for 5x10
7
 
cells, whereas anti-human IL-4Rα and anti-human IL-13Rα1 antibodies were applied in a 
blocking concentration (50μg/ml for 5x107 cells). All treatments were performed for 20 
min. The pre-treatment of lymphocytes with the PKC inhibitor, Staurosporine (Sigma 
Aldrich Inc, Budapest, Hungary) was performed at a concentration of 400ng/ml for 5x10
7
 
cells at 37°C in 5% CO2 for an hour. 
 
5.       Western blotting 
 
            Following the treatment, lymphocytes were washed in PBS and then in PBS 
containing 1mM sodium-vanadate and 5mM NaF by centrifugation. Samples were 
resuspended and centrifuged at 13000 rpm for 40 sec. Pellets were resuspended in 3 
volumes of  buffer containing 20 mM HEPES (pH 7.9), 20 mM NaF, 1mM sodium-
vanadate, 1 mM Na4P2O7, 1mM EDTA, 1mM EGTA, 5mM dithiothreitol (DTT), 0.5mM 
PMSF, aprotinin (0.01μg/ml), leupeptin (0.025μg/ml), 400mM NaCl, 20% glycerol. 
Samples were frozen and thawn three times, and kept on ice for a further 20 min. After 
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centrifugation at 15000 rpm at 4°C for 30 min., the supernatants were collected, and the 
protein content of the extracts was determined. 
            For the detection of different transcription factors in the extracts of lymphocytes, 
25µg of total protein was separated by 7.5% or 12% SDS-PAGE, and transferred to a 
Hybond ECL membrane (Amersham Biosciences, Little Chalfont, UK) overnight at 54 
mA. The blots were blocked with 3% non-fat dry milk in TBS-Tween solution for an 
hour, then incubated with 1:20000 diluted rabbit polyclonal phospho-specific (Tyr-641) 
anti-human STAT6 or with 3 μg/ml rabbit polyclonal phospho-specific (Tyr-693) anti-
human STAT4 or with 1:2000 diluted rabbit polyclonal phospho-specific (Tyr-1022/ Tyr 
1023) anti-human Jak1 or with 1:200 diluted rabbit polyclonal phospho-specific (Tyr-980) 
anti-human Jak3 or with 1:200 diluted rabbit polyclonal anti-human SOCS1 or with 1:200 
diluted rabbit polyclonal anti-human SOCS3 antibodies in TBS-Tween solution 
containing 3% non-fat dry milk for an hour. 
            The blots for detecting PKC factors were blocked with 3% non-fat dry milk in 
TBS-Tween solution for an hour, then incubated with 1:1000 diluted rabbit polyclonal 
phospho-specific anti-human PKCζ or phospho-specific anti-human PKCθ or phospho-
specific anti-human PKCα/β II for 4 hours in TBS-Tween solution containing 3% non-fat 
dry milk. 
            For controlling the loading, 1:1000 diluted rabbit polyclonal anti-human STAT6 or 
1:1000 diluted rabbit polyclonal anti-human STAT4 or 1:1000 diluted rabbit polyclonal 
anti-human Jak1 antibodies or 1:1000 diluted rabbit anti-human β actin antibodies were 
used. After six washing cycles (10 min. each) in TBS-Tween (pH 7.4), the blots were 
incubated at room temperature for 45 min with 1:2000 diluted HRPO-labeled anti-rabbit 
IgG, and then washed six times (10 min. each) in TBS-Tween. Antibody binding was 
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detected using an ECL kit (Perkin Elmer Life Sciences, Boston, MA, USA) according to 
the manufacturer’s instructions. 
 
6.       EMSA Supershift 
 
            Nuclear extracts were prepared as described by Xu and Cooper (76) and all 
subsequent steps were performed at 4 °C. Following the treatment, lymphocytes were 
washed twice in ice cold phosphate buffered saline (PBS) and resuspended in 10 volumes 
of buffer containing 10mM HEPES (pH 7.9), 1.5mM MgCl
2
, 10mM KCl, 0.5 mM DTT, 
protease inhibitors (Complete, Mini EDTA-free tablets, Boehringer Mannheim, 
Mannheim, Germany), phosphatase inhibitors (Phosphatase Inhibitor Coctail, Sigma-
Aldrich Inc., Budapest, Hungary) and placed on ice for 10 min. After vigorous vortexing, 
nuclei were collected by centrifugation in microcentrifuge at 10000 rpm for 10 seconds, 
resuspended in 2 volumes of buffer containing 20 mM HEPES (pH 7.9), 25% glycerol, 
420 mM NaCl, 1.5 mM MgCl
2
, 0.2 mM EDTA, 0.5 mM DTT, protease inhibitors, 
phosphatase inhibitors and placed on ice for 20 min. After centrifugation in a 
microcentrifuge at 10000 rpm for 10 seconds, the supernatants were collected, the protein 
content of the extracts was determined, aliquoted and stored at -80 °C. For shift assay 
analysis STAT6 binding probes (5’ TCGACTTCCCAAGAACAGCA 3’) and their 
reverse complementary pairs were incubated at 80 
o
C for 10 min. in annealing buffer 
containing 100 mM NaCl, 10 mM TRIS (pH 7.5), 1mM EDTA and allowed to cool down 
slowly to room temperature. Double-stranded oligonucleotides were end-labeled with [γ-
32
P]ATP using T4 polynucleotide kinase (Promega Corp. Madison, WI USA) according to 
the manufacturer’s protocol. Binding reactions were performed at room temperature for 
30 min. in 20µl volume, containing 300ng polydIdC, 100mM NaCl, 0.25mM EDTA, 
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1mM DTT, 20mM HEPES (pH 7.9) and 20 fmol 
32
P-labeled oligonucleotide probe. For 
supershift assays the reaction mixtures were pre-incubated with 1µl rabbit anti-human 
STAT6 IgG (2µg/µl) for 1 h at 4 
o
C before adding the 
32
P-labeled oligonucleotide. 
Samples were separated on 3.5% acrylamide gel with 0.5x Tris-Borate-EDTA buffer. The 
gel was dried and exposed to X-ray film. 
 
7.       Phosphatidylinositol-Specific Phospholipase C treatment 
 
            After isolation, washing and PHA treatment of lymphocytes, as described above, 
(5x10
6
 cells/ samples) were incubated with 2.5 Units of PI-PLC (Sigma-Aldrich Inc., 
Budapest, Hungary) in 1 ml of PBS for 30 minutes at 37°C in 5% CO2 and washed twice 
with PBS by centrifugation. 
 
8.       ELISA test for detecting binding of PIBF to IL-4R 
 
            During an overnight incubation at 4 °C, 96 well-microtiter plates were coated with 
100 μl/well of 1 μg/ml and 0.5 μg/ml of soluble recombinant human IL-4Rα (R&D 
Systems Europe Ltd., Abingdon, UK) in 50 mM carbonate buffer (pH 9.6). All further 
incubations were performed at 37oC. Plates were washed three times and free binding sites 
were blocked with PBS containing 0.05% Tween, 0.5% gelatin and 0.1% BSA for an 
hour. The logarithmic dilutions (0.01-1 μg/ml) of 48-kDa N-terminal recombinant human 
PIBF or recombinant human IL-4 in PBS Tween (pH 7.4) were incubated on the plates for 
60 min. The plates were washed 3 times, and incubated with 1:1000 diluted biotin-
conjugated anti-PIBF antibody or 1:1000 diluted goat anti-human IL-4 antibodies for an 
hour. Following 3 further washing cycles, biotin-conjugated anti-PIBF IgG was reacted 
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with 1:1000 diluted streptavidin-biotin-HRPO (Amersham Biosciences, Little Chalfont, 
UK) for 30 min., whereas anti-IL-4 antibody was reacted with 1:2000 diluted HRPO-
labeled anti-goat IgG for 60 min. The latter was then incubated with 1:1000 diluted 
streptavidin-biotin HRPO for 30 min. The reaction was developed with O-
phenylenediamine (ODP) (FLUKA, Sigma-Aldrich Inc., Budapest, Hungary) and the 
reaction was stopped by adding 50 μl of 4M H2SO4. Absorbance was read at 490 nm. 
 
9.       Determination of receptorbinding of PIBF by flow cytometry 
 
            One million peripheral lymphocytes from healthy volunteers were incubated with 
2 μg/ml FITC-conjugated PIBF in the presence of increasing concentrations (0-20 μg/100 
μl) of unlabelled PIBF or monoclonal anti-human IL-4Rα antibody for 30 min. at 4°C. 
After the incubation, the cells were washed in PBS then fixed in 0.5 ml 4% PBS-formalin 
and analyzed by flow cytometry, using a FACSCalibur flow cytometer (BD 
Immunocytometry Systems, BD Biosciences, San Jose, CA, USA) equipped with a 488 
nm excitation laser with the CellQuest software program (BD Biosciences, San Jose, CA, 
USA).  
 
10.       Confocal microscopy 
 
            One million peripheral lymphocytes from healthy volunteers were incubated with 
5 μg of FITC-conjugated PIBF for 20 min at 37 oC. The cells (1x105) were plated on poly-
L-lysine coated slides and incubated at 37 oC for further 10 min., then washed twice in 
PBS containing 1% FCS and fixed with freshly prepared 3 % paraformaldehyde in PBS 
for 10 min. at room temperature. After washing, the plates were incubated with 0.5 μg of  
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monoclonal anti-human IL-4Rα or 2 μl of PE-labeled mouse anti-human CD45RA 
antibody for 45 min. at room temperature. Cells were washed twice and incubated with 2 
μl PE-labelled rat anti-mouse IgG 2A+B or PE-labeled rat anti-mouse IgG1 for 30 min. at 
room temperature. Cells were washed twice and the slides were mounted with DABCO 
(Sigma-Aldich Inc., Budapest, Hungary). To control the specificity of the capping 
formation, all steps were also performed at 4°C. The slides were analyzed with a Biorad 
confocal microscope with 100x objective, using laser excitation at 473 nm and filters 
580+/-16 nm for PE and 522+/-17.5 nm for FITC. Images were analysed using the Adobe 
Photoshop 7.0 program.  
 
11.       RNA intereference (RNAi) and Cytometric Bead Arrays  
 
            Oligonucleotides were hand-designed to interfere exclusively with STAT6 mRNA 
(Ambion Inc., Huntington, UK). As negative control, the very same nucleotides were 
scrambled to form a non-genomic combination (controlled by Pubmed Blast search). 
Oligonucleotide sequences used for STAT6 RNAi were the following: 
- Target Sequence for STAT6    AAG CAG GAA GAA CTC AAG TTT 
- Target Sequence Scrambled    AAA CGA GAG TGT TAT AAC TGT 
Cells were washed twice with Optimem media (Invitrogen, Karlsruhe, Germany). 
Oligonucleotides were dissolved in RNAse-free water and annealed according to the 
guidelines provided by the manufacturer, and incubated for 20 min. at room temperature 
with Oligofectamine (Invitrogene Karlsruhe, Germany). This mixture was added drop-
wise to the cells, until a concentration of 66 nM was reached. After 4 hours incubation at 
37oC, DMEM containing 30% FCS was added to cultures. Western blots for STAT6 
expression were performed 24 hours subsequent to siRNA transfection. 
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            Lymphocytes culture: Lymphocytes (intact, control treated with scrambled oligos 
and those after RNAi) were adjusted to 106 cells/ml in RPMI1640 medium containing 
10% FCS, and cultured for 48 hours at 37°C, 5% CO2 in a humidified atmosphere with 
0.2 or 10 μg/ml of the 48 kDa N-terminal recombinant human PIBF or without PIBF. 
Supernatants were harvested for cytokine determination. Lymphocytes were lysed for 
Western blot analysis. 
            Cytometric Bead Arrays (CBA; Becton Dickinson, San Jose, CA, USA or Bender 
MedSystems, Vienna, Austria) were used to analyze the concentrations of IL-10, TNFα 
and IFNγ in the supernatants of lymphocyte cultures. Supernatants were incubated with 
labelled capture beads and detection reagent for 3hours in the dark at room temperature, 
and analyzed with flow cytometer (FACScalibur, Becton Dickinson, San Jose, CA, USA 
for BD arrays or alternatively Galaxy, Dako, Denmark) by using the respective CBA 
Analysis Software (BD, San Jose, CA, USA) and Bender MedSystem (Bender 
MedSystems, Vienna, Austria) software.  
            Statistical analysis: The two-tailed Student’s t-test was used for statistical 
evaluation of the data. Differences were considered significantly if the p value was equal 
to or lower than 0.05.  
 
12.       Flow cytometric determination of intracellular Ca++  
 
            In peripheral lymphocytes from healthy non-pregnant volunteers intracellular free 
Ca++ was measured using Fluo-3 AM according to the protocol described by Minta et al 
(77, 78). Briefly, 10
6 
cells were incubated for 30 min at room temperature in 100µl tissue 
culture medium containing 10µM Fluo-3 AM. The cell suspensions were diluted with 10 
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ml RPMI containing 10% FCS and incubated for further 30 min. Samples were washed 
twice in RPMI containing 10% FCS. Activation was carried out with ionomycin 
(1µg/10
6
cells) as a non-specific activator (79, 80) or 48-kDa N-terminal recombinant 
human PIBF (5µg/10
6
 and 20µg/10
6
 cells). 7-Aminoactinomycin D (7-AAD) labelling 
was used to distinguish dead cells by their higher fluorescence at 647 nm (FL3 channel). 
The viable cells were gated and all further calculations were performed excluding the 7-
AAD positive cells. Increase of fluorescence was measured in a Becton Dickinson 
FacsCalibur flow cytometer using the CellQuest program. The mean fluorescence 
intensity of Fluo-3 AM dye (proportional to the cytosolic calcium level) was determined 
at 526 nm (FL1 channel). After measuring basal fluorescence at 526 nm, the activating 
agent was added and the measurement continued for further 100 to 400 seconds, enabling 
us to follow the alterations of intracellular free Ca++ level (FL1 fluorescence intensity) in 
function of time. Gates were created along the time axis of the activation dot plots at 
definite time points and the mean fluorescence intensity at 526 nm was statistically 
analyzed from each gate. 
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VI. THESES 
 
            The present data show that neutralization of endogenously produced PIBF by anti-
PIBF antibody results in a more than threefold increase in the precentage of IL-12 positive 
mononuclear cells, which is corrected by simultaneous Q treatment, suggesting, that PIBF 
inhibits IL-12 production via an action on AA metabolism. 
            The possible mechanism might be suggested that the progesterone binding of 
lymphocytes is followed by the release of PIBF that inhibits AA release. The subsequent 
block of PG synthesis reduces IL-12 production and results in lowered NK activity, which 
favours a normal pregnancy outcome.  
            According to the findings in this study we suggest the existence of a novel type of 
IL-4R, where, upon ligation the PIBFR combines with the alpha chain of the IL-4R, and 
induces the phosphorylation of Jak1, which in turn phosphorylates STAT6.             
Phosphorylated STAT6 dimers move to the nucleus, where they activate the expression of 
different genes, probably the SOCS3, which via binding to the IL-12R inhibits the 
phosphorylation of STAT4. 
            Testing the hypothesis that the PIBFR was a GPI anchored protein, we digested 
the anchoring region with PI-PLC. In PI-PLC digested cells, IL-4 was still able to activate 
STAT6, but PIBF failed to do so, suggesting that the latter was a GPI anchored protein, 
indispensable for PIBF to activate STAT6. GPI-deficiency has been shown to cause 
female infertility in mice, but to date the GPI-anchored protein needed for maintaining 
pregnancy has not been identified. Our earlier data show that PIBF depletion ablates 
murine pregnancy, suggesting that the PIBFR might be a considered candidate. 
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            The above findings would explain the previously described cytokine effects of 
PIBF (28), as well as its pregnancy protective (70) and possible tumor promoting effects 
(16).  
            In this study we also show that PIBF, which induces a Th2 dominant cytokine 
pattern, activates the PKC signal transduction pathway. T cells express multiple isotypes 
of PKC, and though it is accepted that PKCs play a role in T cell activation, little is known 
about the function of individual PKC isotypes. Our results show that the Ca++ 
independent, novel protein kinase C isoform PKCθ and the atypical protein kinase C 
isoform ζ are involved the Th2 biased immune response induced by PIBF. 
            Earlier data from our laboratory show that PIBF signals via the IL-4R and this 
results phosphorylation of Jak1 and STAT6. PKCζ activity is required for Jak1 function, 
and in PKCζ deficient cells phosphorylation of STAT6 is dramatically inhibited. We 
recently demonstrated increased PKCζ phosphorylation following PIBF treatment, and 
showed that PKCζ and PKCθ phosphorylation but not that of PKC α/β  are required for 
PIBF-induced Jak1 and STAT6 activation.   
            The first event of PIBF signalling is possibly the phosphorylation of PKCζ, which 
depends on ligation of the IL-4R. Indeed, blocking of the IL-4Rα counteracted the PKC 
activating effect of PIBF. Based on these data we propose the following mechanism; 
following interaction of PIBF with IL-4Rα,  PKCζ gets phosphorylated and activates 
Jak1, which in turn phosphorylates STAT6. 
            Th1 activation is characterized by increased intracellular Ca++ concentrations and 
low PKC signal, while little or no elevation of intracellular free Ca++ concentration 
occurs activation of Th2 cells via TCR complex compared to Th1 cells. In line with the 
finding, that progesterone does not affect lymphocyte Ca++ channels, PIBF induced PKC 
phosphorylation, without any effect on intracellular Ca++ levels.  
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            High PKC activity and low intracellular Ca++ levels favour the development of 
Th2 cytokine sensitive cells. These findings with our earlier data - showing STAT6 
activation by PIBF - might account for the Th2 biased immune response induced by PIBF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50
VII. PAPERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51
VIII. REFERENCES 
 
1. Halme, J. and Woessner, J. F. Effect of progesterone on collagene breakdown and 
tissue collagenolytic activity in the inovulating rat uterus. J. Endocrinol. 1975; 66: 
357. 
2. Lye, S. J. and Porter D. G. Demonstration that progesterone „block” uterine activity in 
the ewe in vivo by a direct action on the myometrium. J. Reprod. Fertil 1978; 52: 87. 
3. Moriyama, I., Sugawa, T. Progesterone facilities implantation of xenogenic cultured 
cells in hamster uterus. Nature New. Biol. 1972; 236: 150. 
4. Hansen, P. J., Bazer, F. W. and Segerson, E. C. Skin graft survival in the uterine 
lumen of ewes treated with progesterone. Am. J. Reprod. Immunol. 1986; 12: 48. 
5. Siiteri, P. K., Febre, F., Clemens, L. E., Chang, R. J., Gondos, B. and Stites, D. P. 
Progesterone and the maintenance of pregnancy: Is progesterone nature’s 
immunsuppressant? Ann. N. Y. Acad. Sci. 1977; 286: 384. 
6. Stites, D. P., Bugbee, S. and Siiteri, P.K. Differential actions of progesterone and 
cortisol on lymphocyte and monocyte interaction during lymphocyte activation – 
relevance to immunosuppression in pregnancy. J. Reprod. Immunol. Microbiol. 1985; 
5: 15. 
7. Szekeres-Bartho J., Csernus, V., Pejtsik, B., Emody, L. and Pacsa, A. S.  Progesterone 
as an immunologic blocking factor in human pregnancy serum. J. Reprod. Immunol. 
1981; 3: 333. 
8. Szekeres-Bartho, J., Csernus, V., Hadnagy, J. and Pacsa, A. S. Immunosuppressive 
effect of serum progesterone during pregnancy depends on the progesterone binding 
capacity of the lymphocytes. J. Reprod. Immunol. 1983; 5: 81. 
 52
9. Szekeres-Bartho, J., Szekeres, Gy., Debre, P., Autran, B. and Chaouat G. reactivity of 
lymphocytes to a progesterone receptor specific monoclonal antibody. Cell. Immunol. 
1990; 125: 273. 
10. Roussev, R. V., Higgins, N. G. and McIntyre, J. A. Phenotypic characterization of 
normal human placental mononuclear cells. J. Reprod. Immunol. 1993; 25: 15. 
11. Paldi, A., d’Auriol, L., Misrahi, M., Bakos A. M., Chaouat G. and Szekeres-Bartho, J. 
Expression of the gene coding for the progesterone receptor in activated human 
lymphocytes. Endoc. J. 1994; 2: 317. 
12. Szekeres-Bartho J. Immunosuppression by progesterone in pregnancy. Monograph. 
Boca Raton, Fl, CRC Press 1992. 
13. Szekeres-Bartho, J., Reznikoff-Etievant, M. F., Varga, P., Pichon, M. F., varga, T. and 
Chaouat, G. Lymphocytic progesterone receptors in normal and pathological human 
pregnancy. J. Reprod. Immunol. 1989; 16: 239. 
14. Szekeres-Bartho, J., Kilar, F., Falkay, G., Csernus, V., Torok, A. and Pacsa, A. S. The 
mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. 
Progesterone-treated lymphocytes release a substance inhibiting cytotoxicity and 
prostaglandin synthesis. Am. J. Reprod. Immunol. 1985; 9: 15. 
15. Rozenblum, E., Vahteristo, P., Sandberg, T., Bergthorsson, J. T., SyrJakoski, K., 
Weaver, D., Haraldsson, K., Johannsdottir, H. K., Vehmanen, P., Nigam, S., 
Golberger, N., Robbins, C., Pak, E., Dutra, A., Gillander, E., Stephan, D. A., Bailey-
Wilson, J., Juo, S. H., Kainu, T., Arason, A., Barkardottir, R B., Nevanlinna, H., Borg, 
A. and Kallioniemi, O. P. A genomic map of a 6-Mb region at 13q21-q22 implicated 
in cancer development: identification and characterization of candidate genes. Hum. 
Genet. 2002; 110: 111. 
 53
16. Lachmann, M., Gelbmann, D., Kalman, E., Polgar, B., Buschle, M., Von Gabain, A., 
Szekeres-Bartho, J. and Nagy, E. PIBF (Progesterone-Induced Blocking Factor) is 
overexpressed in highly proliferating cells and associated with the centrosome. Int. J. 
Cancer 2004; 112: 51. 
17. Polgar, B., Kispal, Gy., Lachmann, M., Paar, C., Nagy, E., Csere, P., Miko, E., 
Szereday, L., Varga, P. and Szekeres-Bartho, J. Molecular cloning and immunological 
characterization of a novel cDNA coding for PIBF. J. Immunol. 2003; 171: 5956. 
18. Szekeres-Bartho, J., Faust, Zs. and Varga, P. The expression of a progesterone-
induced immunomodulatory protein in pregnancy lymphocytes. Am. J. Reprod. 
Immunol. 1995; 34: 342. 
19. Wegmann, T. G.., Lin, H., Guilbert, L. and Mossman, T. H. Bi-directional cytokine 
interactions in the maternal-fetal relationship: successful allopregnancy is a Th2 
phenomenon. Immunol. Today 1993; 14: 353. 
20. Szekeres-Bartho, J., Wegmann, T., Kelemen, K., Bognar, I., Faust, Zs. and Varga, P. 
Interaction of progesterone- and cytokine-mediated immunomodulatory mechanisms 
in favour of successful gestation. Reg. Immunol. 1994; 6: 315. 
21. Szekeres-Bartho, J., Faust, Zs., Varga, P., Szereday, L. and Kelemen, K. The 
immunological pregnancy protective effect of progesterone is maifested via 
controlling cytokine production. Am. J. Reprod. Immunol. 1996; 35: 348. 
22. Szekeres-Bartho, J. and Chacouat, G., Lymphocyte-derived progesterone-induced 
blocking factor corrects resorption in a murine abortion system. Am. J. Reprod. 
Immunol. 1990; 23: 26. 
23. Szekeres-Bartho, J., Kinsky, R. and Chaouat, G. The effect of a progesterone-induced 
immunologic blocking factor on NK-mediated resorption. Am. J. Reprod. Immunol. 
1990; 24: 105. 
 54
24. Hermann, W., Wyss, R., Riondel, A., Philibert, D., Teutsch, G., Sakiz, E. and Baulieu, 
E-E. Effect d’un steroide antiprogesterone chez la femme: interruption du cycle 
menstruel et de la grossesse au debut. C. R. Acad. Sci. Paris 1982; 294: 933. 
25. Philibert, D., Mogiulewsky, M., Mary, I., Lecaque, D., Tourmemine, C., Secchi, J.,  
and Deraedt, R. Pharmacological profile of RU 486 in animals. In: The Antiprogestin 
Steriod RU 486 and Human Fertility Control, eds. Baulieu E-E and Segal J.S., Plenum 
Press, New York, 1985; 49. 
26. Puri, C. P., Kohlkute, S. D., Pongubala, J. M. R. Patil, R. K. Elger, W. A. G and 
Jayaraman, S. Effect of the antiprogestin ZK.98734 on the ovarian cycle, early 
pregnancy and on its binding to progesterone receptors in the myometrium of 
marmoset. Callithrix jacchus, Biol. Reprod. 1988; 38: 528. 
27. Szekeres-Bartho, J., Csernus, V., Hadnagy, J. and Pacsa A. S. Influence of treatment 
of postaglandin synthesis inhibitor or progesterone on cytotoxic activity and 
progesterone binding capacity of lymphocytes during pregnancy. Prostaglandins 1983; 
26: 187. 
28. Szekeres-Bartho, J. and Wegmann T. G. A progesterone-dependent 
immunomodulatory protein alters the Th1/Th2 balance. J. Reprod. Immunol. 1996; 31: 
81. 
29. Rukavina, D., Rubesa G., Gudelj, L., Haller, H. and Podack E. R. Characteristics of 
perforin expressing lymphocytes within the first trimester decidua of human 
pregnancy. Am. J. Reprod. Immunol. 1995; 33: 394. 
30. Ishihara, O., Matsuoka, K., Kinoshita, K., Sullivan M. H. and Elder M. G. Interleukin-
1 beta stimulated PGE2 production from early trimester human decidual cells is 
inhibited by dexamethasone and progesterone. Prostaglandins 1995; 49: 15. 
 55
31. Helvaciouglu, A., Auletta, F. and Scommegna A. Antifertility effect of Azastene 
mediated by prostaglandin. Am. J. Obstet. Gynecol. 1981; 141: 138. 
32. Falkay, G. and Sas M. Correlation between the concentrations of prostaglandin 
dehydrogenase and progesterone in the early human placenta. J. Endocrinol. 1978; 76: 
173. 
33. Szekeres-Bartho J., Csernus, V., Hadnagy, J. and Pacsa A. S. Progesterone-
prostaglandin balance influences lymphocyte function in relation to pregnancy. Am. J. 
Reprod. Immunol. 1983; 4: 139. 
34. Goodwin, J. S. and Webb D. R. Reulation of the immune response by prostaglandins. 
Clin. Immunol. 1980; 15: 106. 
35. Kuehl, F. A. Cirillo, V. J. Zanetti, M. F., Beveridge, G. C. and Ham F. The regulatory 
role of steroids on the PGF/PGE ratio in target tissues. Agents Actions 1976; 61: 65. 
36. Szekeres-Bartho, J., Falkay, G., Torok, A. and Pacsa A. S. Relationship between 
cytotoxicity and the cyclooxigenase pathway of arachinodic acid metabolism. Am. J. 
Reprod. Immunol. 1985; 9: 19. 
37. Xie, W. et al. Mitogen-inducible prostaglandin G/H synthase: a new target for 
nonsterodial antiinflammatory drugs. Drug Dev. Res. 1992; 25: 205. 
38. Romero, R., Mazor, M., Wu, Y. K. Sirtori, M., Oyarzun, E., Mitchell M. D. and 
Hobbins J. C. Infection in the pathogenesis of preterm labor. Semin. Parinatol. 1988; 
12: 262. 
39. Hameed, C., Tejani, N., Vama, U. L. and Archbald F. Silent chorionamnionitis as a 
cause of preterm labor refractory to tocolytic therapy. Am. J. Obstet. Gynecol. 1984; 
149: 726. 
40. Mitchell, M. D., Branch, D. W., Ludin-Schiller, S., Romero R., Daynes, R. A. and 
Dudley D. J. Immunologic aspect of preterm labor. Semin. Perinatol. 1991; 15: 211. 
 56
41. Romero, R., Rolansky, P., Oyarzun, E., Wan, M., Emamiam, M., Novitsky, T. J., 
Gould, M. J. and Hobbins J. C. Labor and infection 2: Bacterial endotoxin in 
amnionitic fluid and its relationship to the onset of preterm labor. Am. J. Obstet. 
Gynecol. 1998; 158: 1044. 
42. Lamont, R. F., Rose, M. P. and Elder M. G. Effect of bacterial products on 
Prostaglandin E production by amnion cells. Lancet 1985; 2: 1331. 
43. Romero, R. J., Hobbins, J. C. and Mitchell, M. D. Endotoxin stimulates prostaglandin 
E2 production by human amnion. Obstet. Gynecol. 1988; 71: 2227. 
44. Bennet, P. R.,  Rose, M. P., Myatt, L. and Elder M. G. Preterm labor: Stimulation of 
arachidonic acid metabolism in human amnion by bacterial products. Am. J. Obstet. 
Gynecol. 1978; 156: 649. 
45. Romero, R., Manogue, K. R., Mitchell, M. D., Wu, Y. K., Oyarsun, E., Hobbins, J. C. 
and Cerami A. Infection and labor IV: Cachectin-tumor necrosis factor in the 
amnionitic fluid of women with intraamnionitic infection and preterm labor. Am. J. 
Obstet. Gynecol. 1989; 161: 336. 
46. Silver, R. M., Edwin S. S., Trautman, M. S., Simmons, D. L., Branch, D. W., Dudley, 
D. J. and Mitchell M. D. Bacterial lipopolysaccharide mediated fetal death. Production 
of newly recognised form in inducible cyclooxigenase (COX) in murine decidua in 
response to lipopolysaccharide. J. Clin. Invest. 1995; 95: 725. 
47. Nakat, T., Fukimoto, M. and Kishimoto, T. Negative regulation of cytokine signaling: 
STAT: induced STAT inhibitor. Trends Biochem. 1999; 24: 394. 
48. Nicholson, S.E., Willson, T. A., Farley, A., Starr, J. G., Zhang, M., Baca, M., 
Alexander, W. S., Metcalf, D., Hilton, D. J. and Nicola, N. A. Mutational analyses of 
the SOCS proteins suggest a dual domain requirement bit distinct mechanisms for 
inhibition of LIF and IL-6 signal transduction. EMBO J. 1999; 18: 375. 
 57
49. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., 
Ohstuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N. and Yoshimura, A. The Jak-binding 
protein Jab inhibits Janus tyrosine kinase activity through binding in the activation 
loop. EMBO J. 1999; 18: 1309. 
50. Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I. and Yoshimura, A. 
CIS3/SOCS3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor 
and JAK2. J. Biol. Chem. 2000; 275: 29338. 
51. Egwuagu, C.   E., Yu, C. R., Zhang, M., Mahdi, R. M., Kim, S. J. and Gery, I. 
Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 
cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 
2002;  168: 3181. 
52. Yamamoto, K., Yamaguchi, M., Miyasaka, N. and Miura, O. SOCS3 inhibits IL-12 
induced STAT4 activation by binding through its SH2 domain to the STAT4 docking 
site in the IL-12 receptor β2 subunit. Biochem. Biophys. Res. Comm. 2003; 310: 
1188. 
53. Newton, A. C. Regulation of protein kinase C. Curr. Opin. Cell. Biol. 1997; 9: 161. 
54. Noble, A., Truman, J. P., Vyas B., Vukmanovic-Stejk, M., Hirst W. J. and Kemeny D. 
M. The balance of protein kinase C and calcium signaling directs T cell subset 
development.  J. Immunol. 2000; 164: 1807. 
55. Noble, A., Thomas, M. J. and Kemeny D. M. Early Th1/Th2 cell polarization in the 
absence of IL-4 and IL-12: T cell receptor signaling regulates the response to 
cytokines in CD4 and CD8 T cells. Eur. J. Immunol. 2001; 31: 2227. 
56. Marsland, B. J., Soos, T. J., Spath, G., Littman, D. R. and Kopf M. Protein kinase  
theta is critical for the development of in vivo T helper (Th) 2 cell but not in Th1 cell 
responses. J. Exp. Med. 2004; 200: 181. 
 58
57. Duran A., Rodriguez A., Martin P., Serrano M., Maria Flores J., Leitges M., Diaz-
Teco M. T. and Moscat, J. Crosstalk between PKCζ and the IL-4/STAT6 pathway 
during T-cell-mediated hepatitis. EMBO 2004; 23: 4595. 
58. Martin, P., Villares R., Rodriguez-Mascarenhas S., Zaballos A., Leitges M., Kovac J., 
Sizing I., Rennert P., Marquez G., Martinez-A. C., Diaz-Meco M. T. and Moscat J. 
Control of T helper 2 cells function and allergic airway inflammation by PKCζ. PNAS 
2005; 102: 9866. 
59. Bradley, L.M., K. Yoshimoto, and S.L. Swain. 1995. The cytokines IL-4, INF-gamma 
and IL-12 regulate the development of subsets of memory effector helper T cells in 
vitro. J. Immunol. 155:1713. 
60. Gajewski, T.F., Schell S. R. and Fitch, F. W. Evidence implicating utilization of 
different T cell receptor-associated signaling pathways by Th1 and Th2 clones J. 
Immunol. 1990; 144: 4110. 
61. Miner, K., and Croft, M. Generation, persistence and modulation of Th0 effector cells: 
role of autocrine IL-4 and INFγ.  J. Immunol. 1998; 160: 5280. 
62. Ho, I. C., Lo, D. and Glimcher, L. H. C-maf promotes T helper cell type  2 (Th2) and 
attenuates Th1 differentation by both interleukin-4-dependent and -independent 
mechanism. J. Exp. Med. 1998; 188: 1859. 
63. Szekeres-Bartho, J., Szekeres, Gy., Debre, P., Autran, B. and Chaouat, G. Reactivity 
of lymphocytes to a progesterone receptor-specific monoclonal antibody. Cell. 
Immunol. 1990; 125: 273. 
64. Par, G., Bartok, B. and Szekeres-Bartho, J. Cyclooxygenase is involved in the effects 
of progesterone-induced blocking factor on the production of interleukin 12. Am. J. 
Obstet. Gynecol. 2000; 183: 126. 
 59
65. Szekeres-Bartho, J., Kilar, F., Falkay, G., Csernus, V., Torok, A. and Pacsa A. S. 
Progesterone-treated lymhocytes of healthy pregnant women release a factor inhibiting 
cytotoxicity and prostaglandin synthesis. Am. J. Reprod. Immunol. Microbiol. 1985; 
9: 15. 
66. Lee, H., Gregory, C. D., Rees, G. B., Scott, I. V. and Golding, P. R. Cytotoxic activity 
and phenotypic analysis of natural killer cells in early normal human pregnancy. J. 
Reprod. Immunol. 1987; 12: 35. 
67. Aoki, K., Kajimura, S., Matsumoto, Y., Ogasawara, M., Okada, S., Yagami, Y., and 
Gleicher, N. Preconceptional natural.killer-cell activity as a predictor of miscarriage. 
Lancet 1995; 345: 1340. 
68. Raghupathy, R., Mutawa, E. A., Makhseed, M., Fawaz, A. and Szekeres-Bartho, J.  
Modulation of cytokine production by dydrogesterone in lymphocytes from women 
with recurrent abortion. Brit. J. Obstet. Gynecol. (in press). 
69. Szereday, L., Varga, P. and Szekeres-Bartho, J. Cytokine production in pregnancy. 
Am. J. Reprod. Immunol. 1997; 38: 418. 
70. Szekeres-Bartho, J., Par, G., Szereday, L., Smart, C. Y. and Achacz, I.  Progesterone 
and non-specific immunological mechanisms in pregnancy. Am. J. Reprod. Immunol. 
1997; 38: 176. 
71. Xu, X., Sun Y. L., and Hoey T. Cooperative DNA binding and sequence-selective 
recognition conferred by the STAT amino-terminal domain. Science 1996; 273: 794. 
72. Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., 
Carson, R. T., Sangster, M. Y., Vignali, D. A.,  Doherty, P. C., Grosveld, G. C. and 
Ihle, J. N. Requirement for STAT4 in IL-12 mediated and responses of natural killer 
and T cells. Nature 1996; 382: 171. 
 60
73. Sledz, C. A. and Williams B. R. G. RNA interference and double-stranded-RNA-
activated pathways. Biochem. Soc. Trans. 2004; 32: 952. 
74. Horejsi, V., Cebecauer, M., Cerny, J., Brdicka, T., Angelisova, P. and Drbal, K. Signal 
transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an 
aspect of immunoreceptor function? Immunol. Lett. 1998; 63: 63. 
75. Alfieri, J. A., Martin, A. D., Takeda, J., Kondoh, G., Myles, D. G. and Primakoff, P. 
Infertility in female mice with an oocyte-specific knockout of GPI-anchored proteins. 
J. Cell. Sci. 2003; 116: 2149. 
76. Xu, W. and Cooper, M. G. Identification of a candidate c-mos repressor that restricts 
transcription of germ cell specific genes. Mol. Cell. Biol. 1995; 15: 5369. 
77. Minta, A., Kao, J. P. and Tsien, R. Y. Fluorescence indicators for cytosolic calcium 
based on rhodamine and flourescein chromophores. J. Biol. Chem. 1989; 264: 8171. 
78. Gergely, L., Cook, L. and Agnello, V. A simplified method for Ca2+ flux 
measurement on isolated human B cells that uses flow cytometry. Clin. Diag. Lab. 
Immunol. 1997; 4: 70. 
79. Mason, M. J. and Grinstein, S. Ionomycin activates electrogenic Ca2+ influx in rat 
thymic lymphocytes.  Biochem. J. 1993; 296: 33. 
80. Morgan, A. J. and Jacob, R. Ionomycin enhances Ca2+ influx by stimulating store-
regulated cation entry and not by a direct action at the plasma membrane. Biochem. J. 
1994; 300: 665. 
 
 
 
 
 
 61
IX. LIST OF PUBLICATIONS 
Paper 1 
Progesterone regulates IL-12 expression in pregnancy lymphocytes by inhibiting 
Phospholipase A2 
G. Par, J. Geli, N. Kozma, P. Varga, J. Szekeres-Bartho 
American Journal of Reproductive Immunology, 2003;49:p:1-5. 
 
Paper 2 
Progesterone-dependent immunomodulation 
J. Szekeres-Bartho, B. Polgar, N. Kozma, E. Miko, G. Par, L. Szereday, A. Barakonyi, T. 
Palkovics, O. Papp, P. Varga 
Chemical Immunology and Allergy, 2005;89:118-125 
  
Paper 3 
The Progesterone-Induced Blocking Factor modulates the balance of PKC and 
intracellular Ca++ 
N. Kozma, M. Halasz, T. Palkovics, J. Szekeres-Bartho 
American Journal of Reproductive Immunology (in press) 
 
Paper 4 
Progesterone-Induced Blocking Factor activates STAT6 via binding to a novel IL-4 
receptor 
N. Kozma, M. Halasz, B. Polgar, T. G. Poehlmann, U. R. Markert, T. Palkovics, M. 
Keszei, G. Par, K. Kiss, J. Szeberényi, L. Grama, J. Szekeres-Bartho 
The Journal of Immunology (in press) 
 62
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 63
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
                  
 
             
 64
       
             
 
 
 
 
 
 
 
 
 
 
 65
TABLE OF CONTENTS 
 
I. LIST OF ABBREVATIONS               4 
 
II. PROLOGUE                5 
 
III. INTRODUCTION                6 
 
1. Progesterone dependent immunomodulation            6 
1.1             Progesterone-Induced Blocking Factor             7 
1.2             Immunological effects of prostaglandins during pregnancy          9 
2. The importance of  Jak/STAT and PKC/Ca++ pathways in cytokine production           11 
2.1               STAT and SOCS signalling                                 11                   
2.2               PKC and Ca++ signalling                                                                14 
 
IV. AIMS OF THE STUDY AND RESULTS                        17 
 
1. Phospholipase A 2 is involved in progesterone-dependent immunoregulation      17 
2. The effects of PIBF on STAT and SOCS signalling         18 
3. PIBF-induced STAT6 activation is mediated by the IL-4 receptor        26 
4. The effects of PIBF on PKC and Ca++ signalling          31 
 
V. MATERIALS AND METHODS            35 
 
1. Antibodies and PIBF             35 
2. LPS, Quinacrine and anti-PIBF treatment          37 
3. Immunocytochemistry                          38 
4. Treatment of lymphocytes for examination of signalling pathways        39 
5. Western blotting             40 
6. EMSA Supershift             42 
 2
7. Phosphatidylinositol-Specific Phospholipase C treatment       43 
8. ELISA test for detecting binding of PIBF to IL-4 receptor       43 
9. Determination of receptorbinding of PIBF by flow cytometry      44 
10. Confocal microscopy           44 
11. RNA intereference (RNAi) and Cytometric Bead Arrays       45 
12. Flow cytometric determination of intracellular Ca++       46 
 
VI. THESES                          48 
 
VII. PAPERS             51 
 
VIII. REFERENCES            52 
 
IX. LIST OF PUBLICATONS           62 
 
         
 
 
 
 
 3
 
 
 
 
 
 
 
 
 

 
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
The Progesterone-Induced Blocking Factor Modulates
the Balance of PKC and Intracellular Ca++
Noemi Kozma1, Melinda Halasz1, Tamas Palkovics1, Julia Szekeres-Bartho1,2
1Department of Medical Microbiology and Immunology, Medical School, Pecs University;
2Reproductive and Tumor Immunology, Research Group of the Hungarian Academy of Sciences, Pecs, Hungary1
Introduction
The protein kinase C (PKC) pathway represents a
major signal transduction system that is activated
following ligand-stimulation of receptors by hor-
mones, neurotransmitters, and growth factors. PKC
plays a critical role in the regulation of differenti-
ation and proliferation in many cell types as well as
in the response to diverse stimuli. To date, 11 PKC
isoenzymes have been described and classified into
three subfamilies:
Conventional, Ca++ dependent protein kinase C
(cPKC) izoforms; a,b,c, or novel Ca++ independent
protein kinase C (nPKC) izoforms; d,e,g,h,l, and
atypical, phospholipase- and Ca++ independent pro-
tein kinase C (aPKC) izoforms; n,i,k.1
Development of naive T cells into type 1 (Th1) or
type 2 (Th2) effector cells is thought to be under the
control of cytokines. Interleukin (IL)-12 and IL-4 are
widely accepted to be the major factors inducing T
cells to develop into type 1 or type 2 cells.2 When
IL-12 and IL-4 are present, murine and human
T-cell differentiation is regulated by the balance of
PKC and calcium signaling within T cells.3 High
levels of PKC activity combined with low calcium
signals favor Th2 development, while predominance
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Problem
Progesterone-induced blocking factor (PIBF) induces Th2 biased cytokine
production; therefore, this study investigates the effects of PIBF on the
protein kinase C (PKC)/Ca++ system – which plays a key role in Th1/Th2
differentiation.
Method of study
Proteins from PIBF-treated cells were reacted on Western blots with
phospho-specific antibodies recognizing different PKC izoforms. Intracel-
lular free calcium was measured by flow cytometry.
Results
Both interleukin (IL)-4 and PIBF induced PKC phosphorylation, which
was abrogated by anti-IL-4Ra or anti-PIBF immunoglobulin G pre-treat-
ment. PIBF treatment did not alter intracellular Ca++ levels. Inhibition
of PKCf or PKCh phosphorylation, but not that of PKCa/b resulted in
the loss of STAT6 and Jak1 phosphorylation by PIBF.
Conclusions
Our data show that PIBF phosphorylates PKC via binding to the IL-4R,
without affecting intracellular Ca++. Phosphorylation of PKCf and PKCh
is required for Jak1 and STAT6 activation, whereas PKCa/b is not
involved. These findings explain the mechanism by which PIBF supports
a Th2 dominant cytokine pattern.
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of calcium signaling with low PKC activity favors
Th1 development.3 Signals downstream of PKC and
calcineurin via activation of transcription factors
directly result in preferential type 1 or type 2 cyto-
kine gene expression.4,5
Progesterone favors a Th2 dominant cytokine
pattern6 and our previous data show that in vitro
treatment of activated lymphocytes with a progester-
one-induced protein [progesterone-induced blocking
factor (PIBF)] leads to increased production of Th2
type of cytokines.7 Lymphocytes from pregnant
women at risk for premature pregnancy termination
produce increased levels of IL-12 together with low
levels of PIBF and IL-10.8 Furthermore, neutraliza-
tion of endogenous PIBF activity in pregnant mice
with anti-PIBF immunoglobulin (Ig) G, results in
increased IFNc production.9 As PIBF exerts its biolo-
gical effects by inducing a Th2 dominant cytokine
production, this study was aimed at investigating the
effects of PIBF on the PKC/Ca++ signal transduction
pathways.
Materials and methods
Recombinant Human PIBF and Antibodies
The 48-kDa N-terminal recombinant human PIBF
was prepared as described earlier.10
Polyclonal anti-PIBF antibodies were generated by
immunizing rabbits with the 48-kDa N-terminal
recombinant human PIBF. IgG was affinity purified
on protein A columns.
Monoclonal anti-human IL-4 receptor a (IL-4Ra)
antibody (from R&D Systems Europe Ltd, Abing-
don, UK) was used for treating lymphocytes. Mouse
IgG2A specific Ig (from Sigma-Aldrich Inc., Buda-
pest, Hungary), and anti rabbit IgG (from Dako,
Glostrup, Denmark) were used as isotype controls.
Rabbit polyclonal phospho-specific (Thr-410/403)
anti-human PKCf, phospho-specific (Thr-538) anti
human PKCh, and phospho-specific (Thr-638/641)
anti-human PKCa/b II (all from Cell Signaling
Technology, Beverly, MA, USA) were used for
blocking and detection of PKC isotypes. Rabbit
polyclonal phospho-specific (Tyr-641) anti-human
STAT6, rabbit polyclonal phospho-specific (Tyr-
1022/Tyr-1023) anti-human Jak1 and HRPO-labeled
anti-rabbit IgG (Dako) were used for Western blot-
ting. Polyclonal rabbit anti-human STAT6, anti-
human Jak1 (both from Santa Cruz Biotechnology
Inc. CA, USA2 ) and rabbit anti-human b actin
(Sigma-Aldrich Inc.) were used for controlling the
loading on Western blots.
Treatment of Lymphocytes
Lymphocytes of healthy non-pregnant volunteers
were isolated from heparinized venous blood on
Ficoll–Paque gradient (Pharmacia, Uppsala, Sweden),
and washed in RPMI 1640 medium (Gibco BRL, Life
Technologies, Paisly, Scotland).
The cells were treated with 1 lg/mL of Phyto-
hemagglutinin (Sigma-Aldrich Inc.) for 24 hr and
then incubated at 37C in 5% CO2 with the
following:
l RPMI medium 1640 (control).
l 48-kDa N-terminal recombinant human PIBF.
l Recombinant human IL-4 (from R&D Systems
Europe Ltd. Abingdon, UK).
l 48-kDa N-terminal recombinant human PIBF
together with anti-PIBF antibody or with anti-
human IL-4Ra antibody, or with phospho-specific
anti-human PKCf, or with phospho-specific PKCh,
or with phospho-specific anti-human PKCa/b II.
l Recombinant human IL-4 together with monoclo-
nal anti-human IL-4Ra antibody, or with phospho-
specific anti-human PKCf, or with phospho-specific
PKCh, or with phospho-specific anti-human PKCa/b
II.
To determine the specificity of the reactions,
lymphocytes were treated with the above antibod-
ies without PIBF. An N-terminal recombinant
human PIBF (48-kDa) and the cytokines were used
at a concentration of 200 ng/mL for 5 · 107 cells,
anti-human IL-4Ra and anti-human PIBF anti-
bodies were applied in a blocking concentration of
50 lg/mL for 5 · 107 cells, and the phospho-
specific PKC antibodies were diluted 1:100 for the
treatments.
All treatments were performed for 20 min. Iso-
type controls were used with each treatment. For
controlling the effect of possible lipopolysaccharide
contamination of recombinant PIBF, parallel lym-
phocyte samples were treated with lysates of
Escherichia coli that had undergone the same purifi-
cation procedure as the recombinant PIBF. Lysate
of E. coli was used in a concentration of 200 ng/mL
for 5 · 107 cells.
Pre-treatment of lymphocytes with the PKC inhib-
itor, Staurosporine (Sigma Aldrich Inc.) was per-
formed at a concentration of 400 ng/mL for 5 · 107
cells at 37C in 5% CO2 for an hour.
KOZMA ET AL.
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Western Blotting
Following the treatment, lymphocytes were washed
in PBS and then in PBS containing 1 mm sodium-
vanadate and 5 mm NaF by centrifugation
(3 13,000 rpm for 40 s). Pellets were resuspended in
3· volumes of buffer containing 20 mm HEPES (pH
7.9), 20 mm NaF, 1 mm sodium-vanadate, 1 mm
Na4P2O7, 1 mm ethylenediaminetetraacetic acid,
1 mm ethyleneglycoltetraacetic acid, 5 mm dithio-
threitol, 0.5 mm phenylmethylsulphonyl fluoride,
aprotinin (0.01 lg/mL), leupeptin (0.025 lg/mL),
400 mm NaCl, 20% glycerol. Samples were frozen
and thawn three times, and kept on ice for a further
20 min. After centrifugation at4 15,000 rpm at 4C
for 30 min, the supernatants were collected, and the
protein content of the extracts was determined. For
detection of different transcription factors in the
extracts 25 lg of total protein was separated by
7.5% SDS-PAGE, and transferred to a Hybond ECL
membrane (Amersham Biosciences, Little Chalfont,
UK) overnight at 54 mA. The blots were blocked
with 3% non-fat dry milk in TBS-Tween solution for
an hour, then incubated with 1:1000 diluted rabbit
polyclonal phospho-specific anti-human PKCf or
phospho-specific anti human PKCh or phospho-spe-
cific anti-human PKCa/b II for 4 hr or with 1:20,000
diluted rabbit polyclonal phospho-specific anti-
human STAT6, or with 1:2000 diluted rabbit poly-
clonal phospho-specific anti-human Jak1 for 1 hr in
TBS-Tween solution containing 3% non-fat dry
milk. For controlling the loading 1:1000 diluted rab-
bit polyclonal anti-human STAT6 or 1:1000 diluted
rabbit polyclonal anti-human Jak1 antibodies or
1:1000 diluted rabbit anti-human b actin antibodies
were used. After three washing cycles (10 min each
in TBS-Tween pH 7.4), the blots were incubated at
room temperature for 45 min with 1:2000 diluted
HRPO-labeled anti-rabbit IgG, and then washed six
times (10 min each) in TBS-Tween. Antibody bind-
ing was detected using an ECL kit (Perkin Elmer Life
Sciences, Boston, MA, USA) according to the manu-
facturer’s instructions.
Flow Cytometric Determination of Intracellular
Ca++
In peripheral lymphocytes from healthy non-preg-
nant volunteers intracellular free calcium was meas-
ured using Fluo-3 AM according to the protocol
described by Minta et al.11,12
Briefly, 106 cells were incubated for 30 min at
room temperature in 100 lL tissue culture medium
containing 10 lm Fluo-3 AM. The cell suspensions
were diluted with 10 mL RPMI containing 10% FCS
and incubated for further 30 min. Samples were
washed twice in RPMI containing 10% FCS. Activa-
tion was carried out with ionomycin (1 lg/106 cells)
as a non-specific activator13,14 or 48-kDa N-terminal
recombinant human PIBF (5 lg/106 and 20 lg/106
cells). 7-Aminoactinomycin D (7-AAD) labeling was
used15 to distinguish dead cells by their higher fluor-
escence at 647 nm (FL3 channel). The viable cells
were gated and all further calculations were per-
formed excluding the 7-AAD positive cells. Increase
of fluorescence was measured in a Becton Dickinson
FacsCalibur flow cytometer using the CellQuest pro-
gram. The mean fluorescence intensity of Fluo-3 AM
dye (proportional to the cytosolic calcium level) was
determined at 526 nm (FL1 channel). After measur-
ing basal fluorescence at 526 nm, the activating agent
was added and the measurement continued for fur-
ther 100–400 s, enabling us to follow the alterations
of intracellular free calcium level (FL1 fluorescence
intensity) in function of time. Gates were created
along the time axis of the activation dot plots at def-
inite time points and the mean fluorescence intensity
at 526 nm was statistically analyzed from each gate.
Results
PIBF Induces PKC Phosphorylation Without
Affecting Intracellular Ca++ Levels
In order to investigate the possible involvement of
the PKC/Ca++ signaling pathway in cytokine effects
of PIBF, we tested the impact of PIBF treatment on
PKC phosphorylation.
Following incubation of lymphocytes with 48-kDa
N-terminal recombinant human PIBF or recombin-
ant human IL-4 the cells were lysed, proteins were
separated on SDS-PAGE, blotted to nitrocellulose
and reacted with phospho-specific antibodies recog-
nizing the PKC izoforms; PKCa/b II, PKCh and PKCf.
Both IL-4 and PIBF treatment resulted in phosphory-
lation of all three PKC izoforms (Fig. 1).
Intracellular free calcium in PIBF-treated periph-
eral lymphocytes was determined by flow cytometry.
Lymphocytes treated with the non-specific activator
ionomycin served as positive controls. Fig. 2 shows
that PIBF-treatment did not alter intracellular Ca++
levels.
PIBF MODULATES PKC ACTIVITY
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PIBF Phosphorylates PKC via Binding to the IL-4
Receptor a Chain
Since earlier data suggest that PIBF uses the IL-4Ra
chain for STAT6 signaling, we tested whether func-
tional IL-4Ra was required for PKC activation. The
effect of PIBF on the phosphorylation of the three
PKC izoforms was abrogated by pre-treatment of the
cells with blocking concentrations of anti IL-4Ra
antibody or anti-PIBF IgG (Fig. 3).
Inhibition of PKC Phosphorylation Counteracts the
Effects of PIBF on Jak1 and STAT6
Recent evidence suggests that PKCf activity is nee-
ded for Jak1 function.165 Therefore we investigated
the requirement of PKC phosphorylation for Jak1
and STAT6 activation by PIBF. Lymphocytes were
treated with PIBF in the presence of the PKC
inhibitor Staurosporine and the cell lysates were
reacted on a Western blot with anti-phospho-STAT6
or anti-phospho-Jak1 antibodies. Inhibition of PKC
activity abrogated PIBF-induced Jak1- and STAT6
phosphorylation (Fig. 4). The use of PKC isotype
specific antibodies in place of the PKC inhibitor
revealed that blocking PKCf, and PKCh with specific
antibodies, interfered with PIBF-induced Jak1- and
STAT6 phosphorylation. Blocking of PKCa/b had no
effect (Fig. 5).
Discussion
In this paper, we show that the PIBF – which indu-
ces a Th2 dominant cytokine pattern and exerts a
oc.EFBIP4-LI0 IP4-LI0il FB 0iloc.E IP4-LI iloc.EFB
CKP ζ CKP θ CKP β/α II
aDk67
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Fig. 110 The effect of progesterone-induced blocking factor (PIBF) on phosphorylation of protein kinase C (PKC) izoforms. Proteins from lysates of
PIBF-treated cells were separated on SDS-PAGE, blotted to nitrocellulose membranes and reacted with phospho-specific antibodies recognizing the
PKC izoforms; PKCf, PKCh and PKCa/b II. Controls include the lysates of untreated cells, and since the recombinant PIBF was produced by Escheri-
chia coli, lysate of the bacterium which had been treated the same way as recombinant PIBF during purification.
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Fig. 210 The effect of progesterone-induced bl-
ocking factor (PIBF) on intracellular Ca++ lev-
els. Intracellular calcium levels were
determined in PIBF-treated cells by flow cy-
tometry. Ionomycin treated cells were used as
positive controls.
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pregnancy protective effect in mice – activates the
PKC signal transduction pathway. The Ca++ inde-
pendent, novel PKC izoform PKCh and the atypical
PKC izoform f are involved the Th2 biased immune
response induced by PIBF.
Progesterone-induced blocking factor treatment
results in increased Th2 cytokine production both in
vitro7 and in vivo,17 and recent data suggest that the
above effects are mediated by the Jak/STAT signal
transduction pathway (N. Kozma et al. unpublished
data6 ).
The balance of PKC activity versus calcium signa-
ling is thought to be important in type1/type2 differ-
entiation. Th1 and Th2 T lymphocyte subsets have
been shown to utilize different signaling mecha-
nisms. Th1 activation is characterized by increased
intracellular Ca++ concentrations and low PKC
signal, while little or no elevation of intracellular
free calcium concentration occurs following activa-
tion of Th2 cells via TCR complex compared with
Th1 cells.4,18 In line with the finding, that progester-
one does not affect lymphocyte Ca++ channels18 –
PIBF induced PKC phosphorylation, without any
effect on intracellular Ca++ levels.
T cells express multiple isotypes of PKC, and
though it is accepted that PKCs play a role in T-cell
activation, little is known about the function of indi-
vidual PKC isotypes.
WB ohpsohp-a:
CKP)146/836rhT( β/α II
WB ohpsohp-a:
CKP)304/014rhT( ζ
WB ohpsohp-a:
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0 4-LI IPFBIP FBIPFB 4-LI itna itna iloc.E
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67 aDk
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Fig. 310 Blocking of the interleukin (IL)-4Ra
inhibits progesterone-induced blocking factor
(PIBF)-induced protein kinase C (PKC) phos-
phorylation. Lymphocytes were treated with
PIBF in the presence of a monoclonal anti-
IL-4Ra antibody. The cells were lysed and the
proteins were separated on SDS-PAGE, blotted
to nitrocellulose and reacted with phospho-
specific antibodies recognizing the PKC izo-
forms; PKCa/b II, PKCf and PKCh. Controls
include the lysates of untreated cells and,
lysates of Escherichia coli.
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Fig. 410 Inhibition of protein kinase C (PKC)
activity prevents progesterone-induced block-
ing factor (PIBF)-induced phosphorylation of
STAT6 and Jak1. Lymphocytes were treated
with PIBF in the presence of the PKC inhibitor
Staurosporine (Stauro) and the cell lysates
were reacted on a Western blot with anti-
phospho STAT6 or anti-phospho Jak1 anti-
bodies.
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Protein kinase Ch and PKCf are both involved in
the induction of type 2 development.19,20 PKCf defi-
ciency leads to impaired secretion of Th2 cytokines
because of the inability of PKCf)/) CD4+ T cells to
differentiate adequately along the Th2 lineage.16
PKCf)/) mice have a defect in Th2 cells but not in
naive T-cell proliferation.21 In case of PKCh)/) mice,
the alterations are not restricted to the Th2 differen-
tiation program,20–23 implying that the role of PKCh
has a broader impact in T-cell function.
In this study PIBF phosphorylated PKCf, PKCh,
and PKCa/b in absence, but not in the presence of
an anti-IL-4Ra antibody, suggesting that a functional
IL-4Ra is needed for PIBF-induced PKC-activation.
Earlier data from our laboratory (N. Kozma et al.
unpublished data7 ) show that PIBF signals via the IL-
4R and this results in phosphorylation of Jak1 and
STAT6.
Protein kinase Cf activity is required for Jak1
function. Upon IL-4 signaling PKCf phosphorylates
Jak1,16 and in PKCf deficient cells phosphorylation
of STAT6 is dramatically inhibited.21 In this study
we demonstrated increased PKCf phosphorylation,
following PIBF treatment, and showed that PKCf
and PKCh phosphorylation but not that of PKC a/b
are required for PIBF-induced Jak1 and STAT6 acti-
vation. The first event of PIBF signaling is possibly
the phosphorylation of PKCf, which depends on
ligation of the IL-4 receptor.16 Indeed, blocking of
the IL-4Ra counteracted the PKC activating effect of
PIBF. Based on these data we propose the following
mechanism; following interaction of PIBF with
IL-4Ra, PKCf gets phosphorylated and activates
Jak1, which in turn phosphorylates STAT6. Intracel-
lular Ca++ concentrations at the same time remain
unchanged.
High PKC activity and low intracellular calcium
levels favor the development of Th2 cytokine
sensitive cells. These findings with our earlier
(8 unpublished) data – showing STAT6 activation by
PIBF – might account for the Th2 biased immune
response induced by PIBF (Fig. 6).
-LI0 4 na4-LIFBIPFBIP iloc.Eit
CKPitnaitna θ
CKP θ CKP θ
iloc.Eitna4-LIFBIPFBIP4-LI0
CKPitnaitna ζ
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Fig. 5 The effect of blocking protein kinase C
(PKC) activity by izoform specific antibodies
on progesterone-induced blocking factor
(PIBF)-induced Jak1 and STAT6 phosphoryla-
tion. PIBF-treated cells were incubated with
blocking concentrations of PKCf, PKCh or
PKCa/b II. The proteins from the cell lysates
were separated on SDS-PAGE, blotted to nitro-
cellulose and reacted with anti-phospho
STAT6 or anti-phospho Jak1 antibodies.
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R
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Activation of Th2 responsive
genes
Fig. 6 Protein kinase C (PKC) activation is a required step in prog-
esterone-induced blocking factor (PIBF) signaling to achieve Th2 dom-
inance. Engagement of the PIBF receptor results in PKC
phosphorylation. Activated PKC will phosphorylate Jak1, which in turn
phosphorylates STAT6. STAT6 dimers are formed, move to the nuc-
leus, where they activate Th2 responsive genes.
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Progesterone-Induced Blocking Factor Activates STAT6 via
Binding to a Novel IL-4 Receptor1
Noemi Kozma,* Melinda Halasz,* Beata Polgar,* Tobias G. Poehlmann,¶ Udo R. Markert,¶
Tamas Palkovics,* Marton Keszei, Gabriella Par,* Katalin Kiss,† Jozsef Szeberenyi,†
Laszlo Grama,‡ and Julia Szekeres-Bartho2*§
Progesterone-induced blocking factor (PIBF) induces Th2-dominant cytokine production. Western blotting and EMSA revealed
phosphorylation as well as nuclear translocation of STAT6 and inhibition of STAT4 phosphorylation in PIBF-treated cells. The
silencing of STAT6 by small interfering RNA reduced the cytokine effects. Because the activation of the STAT6 pathway depends
on the ligation of IL-4R, we tested the involvement of IL-4R in PIBF-induced STAT6 activation. Although PIBF does not bind to
IL-4R, the blocking of the latter with an Ab abolished PIBF-induced STAT6 activation, whereas the blocking of the IL-13R had
no effect. PIBF activated suppressor of cytokine signaling-3 and inhibited IL-12-induced suppressor of cytokine signaling-1 ac-
tivation. The blocking of IL-4R counteracted all the described effects, suggesting that the PIBF receptor interacts with IL-4R
-chain, allowing PIBF to activate the STAT6 pathway. PIBF did not phosphorylate Jak3, suggesting that the -chain is not
needed for PIBF signaling. Confocal microscopic analysis revealed a colocalization and at 37°C a cocapping of the FITC PIBF-
activated PIBF receptor and PE anti-IL-4R-labeled IL-4R. After the digestion of the cells with phosphatidylinositol-specific
phospholipase C, the STAT6-activating effect of PIBF was lost, whereas that of IL-4 remained unaltered. These data suggest the
existence of a novel type of IL-4R composed of the IL-4R -chain and the GPI-anchored PIBF receptor. The Journal of Im-
munology, 2006, 176: 819–826.
T he progesterone-induced blocking factor (PIBF)3 is codedon locus 13q21-q22, which has been implicated as a com-mon site for somatic deletions in a variety of malignant
tumors (1), and the protein has been identified in undifferentiated
cells and in malignancies (2). The molecule was initially discov-
ered as a progesterone-induced protein (hence the name), mediat-
ing the immunological effects of progesterone (3). PIBF produc-
tion is a characteristic feature of normal human pregnancy,
whereas the lack of PIBF predicts spontaneous pregnancy termi-
nation (4). The neutralization of endogenous PIBF results in al-
tered cytokine production and pregnancy termination in mice (5).
PIBF induces a Th2-biased cytokine production in vitro (6) and in
vivo (7).
STAT proteins were identified as transcription factors mediating
virtually all cytokine driven signaling (8–10). STAT4 is needed
for generation of Th1 cells (11), whereas STAT6-deficient mice
fail to respond to IL-4, suggesting the importance of STAT6 in the
activation of IL-4 inducible genes (10).
Suppressor of cytokine signaling (SOCS) proteins negatively
regulate the signal transduction of several cytokines (12–14).
SOCS-1 and SOCS-3 genes are induced by a variety of cytokines,
IL-4 among others (15). CD4 naive T cells constitutively express
low levels of both SOCS-1 and SOCS-3 mRNA, and the differ-
entiation into the Th1 or Th2 phenotype is accompanied by pref-
erential expression of distinct SOCS mRNA transcripts and pro-
teins (16).
IL-4R is a heterodimeric cytokine receptor system consisting of
the signaling high-affinity -chain and a transactivating low-affin-
ity chain that can either be the common -chain or the IL-13R
1-chain (17). The extracellular domain of the IL-4R -chain pro-
vides nearly the complete ligand-binding affinity of the whole
receptor (18). IL-4R - and -chains associate with the Janus ki-
nases, Jak1 and Jak3, respectively (19). Ligand-induced het-
erodimerization of IL-4R - and -chains induces tyrosine phos-
phorylation of IL-4R and activation of Jak1 and Jak3 (20).
Phosphorylated tyrosine residues of IL-4R serve as anchor for the
Src homology 2 domain of STAT6, which gets phosphorylated
(21) and forms homodimers. These translocate to the nucleus and
bind to DNA sequences TTCNNN(N)GAA in the promoter region
of IL-4 responsive genes (22).
PIBF exerts its biological effects by inducing a Th2-biased cy-
tokine production, therefore, we investigated the effects of PIBF on
the STAT6/STAT4 signaling pathways, and because activation of
the STAT6 pathway is initiated through IL-4R, the possibility that
PIBF signals via IL-4R was investigated.
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Materials and Methods
Abs and PIBF
The 48-kDa N-terminal recombinant human PIBF was prepared as de-
scribed earlier (3) and is referred to as PIBF throughout our report. Poly-
clonal anti-PIBF Abs were generated by immunizing rabbits with the 48-
kDa N-terminal recombinant human PIBF. IgG was affinity purified on
protein A columns.
Monoclonal anti-human IL-4R as well as goat anti-human IL-13R1
Abs (all from R&D Systems) were used for treating lymphocytes. Mouse
IgG2A-specific Ig (Sigma-Aldrich), and rabbit IgG-specific and goat IgG-
specific Abs (both from DakoCytomation) were used as isotype controls.
Rabbit polyclonal phospho-specific (Tyr641) anti-human STAT6, phospho-
specific (Tyr1022/Tyr1023) anti-human Jak1, phospho-specific (Tyr980) anti-
human Jak3, anti-human SOCS-1, anti-human SOCS-3 Abs (all from Santa
Cruz Biotechnology), rabbit polyclonal phospho-specific (Tyr693) anti-
human STAT4 Ab (Zymed Laboratories), and HRP-labeled anti-rabbit IgG
(DakoCytomation) were used for Western blotting. Polyclonal rabbit anti-
human STAT6, anti-human Jak1, anti-human STAT4 Abs (all from Santa
Cruz Biotechnology), and rabbit anti-human -actin (Sigma-Aldrich) were
used for controlling the loading on Western blots. Polyclonal rabbit anti-
human STAT6 Ab recommended for gel supershift studies (Santa Cruz
Biotechnology) was used for EMSA supershift. Goat polyclonal anti-
human IL-4 (R&D Systems), mouse monoclonal anti-human IL-4R,
HRP-labeled anti-goat IgG (both from DakoCytomation), streptavidin-bi-
otin-HRP (Amersham Biosciences), and polyclonal biotin-conjugated anti-
PIBF Abs (prepared in our laboratory) were used for ELISA. Mouse mono-
clonal anti-human IL-4R, PE-labeled rat anti-mouse IgG2A and IgG2B
(BD Biosciences), FITC-conjugated PIBF (prepared in our laboratory), PE-
labeled mouse, anti-human CD45RA (BD Biosciences), and PE-labeled rat
anti-mouse IgG1 (BD Biosciences) were used for immunofluorescence
confocal microscopy. PIBF-FITC and mouse monoclonal anti-human IL-
4R Abs were used for determining the receptor binding of PIBF by flow
cytometry.
Treatment of lymphocytes
Ficoll-Paque (Pharmacia) isolated PBL from healthy volunteers were
washed in RPMI 1640 medium (Invitrogen Life Technologies), treated
with 1 g/ml PHA (Sigma-Aldrich) for 24 h, and then incubated at 37°C
in 5% CO2 with the following: RPMI 1640 medium; 10, 20, and 200 ng/ml
and 0.5, 1, and 10 g/ml PIBF for 5  107 cells; PIBF, progesterone
(Sigma-Aldrich) or recombinant human IL-4 (R&D Systems) for 1, 10, 20,
and 30 min and 24 h; recombinant human IL-4 plus recombinant human
IL-12 (both from R&D Systems), or rIL-4 plus rIL-12 plus monoclonal
anti-IL-4R Ab, or rIL-4 plus monoclonal anti-IL-4R Ab; PIBF plus
polyclonal anti-PIBF Ab, or PIBF plus monoclonal anti-IL-4R Ab, or
PIBF plus rIL-12 plus monoclonal anti-IL-4R Ab, or PIBF plus rIL-12
plus monoclonal anti-IL-13R1 Ab; rIL-12 plus PIBF or PIBF plus rIL-12
plus recombinant human IL-4; lysate of Escherichia coli that had under-
gone the same purification procedure as the recombinant human PIBF in a
concentration of 200 ng/ml; and isotype controls used with each treatment.
The cytokines, PIBF, and progesterone were used at a concentration of
200 ng/ml for 5  107 cells, whereas anti-human IL-4R and anti-human
IL-13R1 Abs were applied in a blocking concentration (50 g/ml for 5
107 cells). All treatments were performed for 20 min.
Western blotting
Following treatment, lymphocytes were washed in PBS and then in PBS
containing 1 mM sodium vanadate and 5 mM NaF. After centrifugation at
13,000 rpm for 40 s pellets were resuspended in 3 volumes of buffer
containing 20 mM HEPES (pH 7.9), 20 mM NaF, 1 mM sodium vanadate,
1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 5 mM DTT, 0.5 mM PMSF,
aprotinin (0.01 g/ml), leupeptin (0.025 g/ml), 400 mM NaCl, and 20%
glycerol. Samples were frozen and thawed three times and kept on ice for
a further 20 min. After centrifugation at 15,000 rpm at 4°C for 30 min,
supernatants were collected, and the protein content of the extracts was
determined. The 25 g of total protein was separated on 7.5 or 12% SDS-
PAGE and transferred to a Hybond ECL membrane (Amersham Bio-
sciences) overnight at 54 mA. The blots were blocked with 3% nonfat dry
milk in TBS-Tween solution for 60 min, then incubated with 1/20,000
diluted phospho-specific anti-STAT6 or with 3 g/ml phospho-specific
anti-STAT4, 1/2000 diluted phospho-specific anti-Jak1, 1/200 diluted
phospho-specific anti-Jak3, or with 1/200 diluted anti-SOCS-1, or with
1/200 diluted anti-SOCS-3 Abs in TBS-Tween solution containing 3%
nonfat dry milk for 1 h. For controlling the loading, 1/1000 diluted anti-
STAT6, 1/1000 diluted anti-STAT4, 1/1000 diluted anti-Jak1 Abs, or
1/1000 diluted anti--actin Abs was used. After six washing cycles (10 min
each) in TBS-Tween (pH 7.4), the blots were incubated at room temper-
ature for 45 min with 1/2000 diluted HRP-labeled anti-rabbit IgG, and then
washed six times (10 min each) in TBS-Tween. Ab binding was detected
using an ECL kit (PerkinElmer) according to the manufacturer’s
instructions.
EMSA supershift
Nuclear extracts were prepared as described by Xu and Cooper (23). Lym-
phocytes were washed twice in ice-cold PBS and resuspended in 10 vol-
umes of buffer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10
mM KCl, 0.5 mM DTT, protease inhibitors (complete, Mini EDTA-free
tablets; Boehringer Mannheim), phosphatase inhibitors (Phosphatase In-
hibitor Cocktail; Sigma-Aldrich) and placed on ice for 10 min. After vig-
orous vortexing, nuclei were collected by centrifugation in microcentrifuge
at 10,000 rpm for 10 s, resuspended in 2 volumes of buffer containing 20
mM HEPES (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 0.5 mM DTT, protease inhibitors, and phosphatase inhibitors
and incubated on ice for 20 min. After centrifugation (10,000 rpm for 10 s)
supernatants were collected and the protein content of the extracts was
determined, aliquoted, and stored at 80°C. For the shift assay, STAT6
binding probes (5-TCGACTTCCCAAGAACAGCA-3) and their reverse
complementary pairs were incubated at 80°C for 10 min in annealing buffer
containing 100 mM NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA and allowed
to cool down slowly to room temperature. Double-stranded oligonucleo-
tides were end-labeled with [-32P]ATP using T4 polynucleotide kinase
(Promega) according to the manufacturer’s protocol. Binding was per-
formed at room temperature for 30 min in 20 l volume, containing 300 ng
of poly(deoxyinosinic-deoxycytidylic acid), 100 mM NaCl, 0.25 mM
EDTA, 1 mM DTT, 20 mM HEPES (pH 7.9), and 20 fmol 32P-labeled
oligonucleotide probe. For supershift assays the reaction mixtures were
preincubated with 1 l of rabbit anti-human STAT6 IgG (2 g/l) for 1 h
at 4°C before adding the 32P-labeled oligonucleotide. Samples were sep-
arated on 3.5% acrylamide gel with 0.5 Tris-borate-EDTA buffer. The
gel was dried and exposed to x-ray film.
Phosphatidylinositol-specific phospholipase C (PI-PLC)
treatment
A total of 5  106 PHA treated lymphocytes was incubated with 2.5 U of
PI-PLC (Sigma-Aldrich) in 1 ml of PBS for 30 min at 37°C in 5% CO2, and
washed twice with PBS.
ELISA for detecting PIBF binding to IL-4R
During an overnight incubation at 4°C, 96-well microtiter plates were
coated with 1 and 0.5 g/ml soluble recombinant human IL-4R (R&D
Systems) in 50 mM carbonate buffer (pH 9.6). All further incubations were
performed at 37°C. Plates were washed three times and free binding sites
were blocked with PBS containing 0.05% Tween, 0.5% gelatin, and 0.1%
BSA for 60 min. Logarithmic dilutions (0.01–1 g/ml) of PIBF or rIL-4 in
PBS Tween (pH 7.4) were incubated on the plates for 60 min. The plates
were washed three times and incubated with 1/1000 diluted biotin-conju-
gated anti-PIBF IgG or 1/1000 diluted goat anti-IL-4 for 60 min. Following
three further washing cycles, biotin-conjugated anti-PIBF IgG was reacted
with 1/1000 diluted streptavidin-biotin-HRP for 30 min, while anti-IL-4 Ab
was reacted with 1/2000 diluted HRP-labeled anti-goat IgG for 60 min. The
reaction was developed with O-phenylenediamine (FLUKA; Sigma-Al-
drich) and stopped by adding 50 l of 4 M H2SO4. Absorbance was read
at 490 nm.
Determination of receptor binding of PIBF by flow cytometry
One million PBL from healthy volunteers were incubated with 2 g/ml
FITC-conjugated PIBF in the presence of increasing concentrations (0–200
g/ml) of unlabeled PIBF or monoclonal anti-IL-4R Ab for 30 min at
4°C. The cells were washed in PBS, fixed in 0.5 ml 4% PBS-formalin, and
analyzed by flow cytometry, using a FACSCalibur flow cytometer
equipped with a 488-nm excitation laser with the CellQuest software pro-
gram (both from BD Biosciences).
Confocal microscopy
One million PBL from healthy volunteers were incubated with 5 g of
FITC-conjugated PIBF for 20 min at 37°C. A total of 1  105 cells was
plated on poly-L-lysine-coated slides and incubated at 37°C for further 10
min, then washed twice in PBS containing 1% FCS and fixed with freshly
prepared 3% paraformaldehyde in PBS for 10 min at room temperature.
After washing, the plates were incubated with 0.5 g of monoclonal
anti-IL-4R or 2 l of PE-labeled mouse anti-CD45RA Ab for 45 min at
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room temperature. Cells were washed twice and incubated with 2 l of
PE-labeled rat anti-mouse IgG2A and IgG2B or PE-labeled rat anti-mouse
IgG1 for 30 min at room temperature. Cells were washed twice and the
slides were mounted with DABCO (Sigma-Aldrich). To control the spec-
ificity of capping formation, all steps were also performed at 4°C. The
slides were analyzed with a Bio-Rad confocal microscope with 100 ob-
jective, using laser excitation at 473 nm with filters 580  16 nm for PE
and 522  17.5 nm for FITC. Images were analyzed using the Adobe
Photoshop 7.0 software.
RNA interference
Oligonucleotides were hand-designed to interfere exclusively with STAT6
mRNA (Ambion). As a negative control, the same nucleotides were scram-
bled to form a nongenomic combination (controlled by basic local align-
ment search tool). Oligonucleotide sequences used for STAT6 RNA inter-
ference were target sequence for STAT6 AAG CAG GAA GAA CTC
AAG TTT and target sequence scrambled AAA CGA GAG TGT TAT
AAC TGT.
Cells were washed twice with OptiMEM (Invitrogen Life Technolo-
gies). Oligonucleotides were dissolved in RNase-free water, annealed ac-
cording to the guidelines provided by the manufacturer, and incubated for
20 min at room temperature with Oligofectamine (Invitrogen Life Tech-
nologies). This mixture was added dropwise to the cells, until a concen-
tration of 66 nM was reached. After 4 h incubation at 37°C, DMEM con-
taining 30% FCS was added to cultures. Western blots for STAT6
expression were performed 24 h subsequent to small interfering (si)RNA
transfection. STAT6 expression was markedly reduced, whereas STAT2
and STAT4 expressions were not affected (see Fig. 2A).
Lymphocyte cultures
Intact lymphocytes, those treated with scrambled oligonucleotides and
those after RNA interference were adjusted to 106 cells/ml in RPMI 1640
with 10% FCS, and cultured for 48 h at 37°C, 5% CO2 in a humidified
atmosphere together with 0.2 or 10 g/ml PIBF or without PIBF. Super-
natants were harvested for cytokine determination. Lymphocytes were
lysed for Western blot analysis.
Cytometric bead arrays
IL-10, TNF-, and IFN- concentrations were determined by Cytometric
Bead Array (CBA; BD Biosciences or Bender MedSystems). Supernatants
were incubated with labeled capture beads and detection reagent for 3 h in
the dark at room temperature, and analyzed with flow cytometer (FACS-
Calibur; BD Biosciences for BD arrays or alternatively Galaxy; DakoCy-
tomation) by using the respective CBA Analysis software (BD Bio-
sciences) and Bender MedSystems software.
Statistical analysis
The two-tailed Student’s t test was used for statistical evaluation of the
data. Differences were considered significant if the value for p  0.05.
Results
PIBF activates STAT6
To test whether the previously described cytokine effects of PIBF
were mediated by the Jak/STAT pathway, cytoplasmic fractions of
PIBF-treated or untreated human PBL were separated on SDS-
PAGE, blotted to nitrocellulose membranes, and reacted with anti-
phospho-STAT6 Abs. Controls included the lysate of E. coli that
had undergone the same purification procedure as the recombinant
PIBF, as well as isotype controls. Similar to IL-4, PIBF induced
STAT6 phosphorylation, which was inhibited by a neutralizing
anti-PIBF IgG (Fig. 1A). To clarify whether PIBF induces nuclear
translocation of phosphorylated STAT6 dimers, nuclear extracts
prepared from PIBF-treated cells, and those from IL-4-treated as
FIGURE 1. PIBF activates STAT6. A, PIBF treatment induces STAT6 phosphorylation. Cytoplasmic fractions of untreated human PBL, and those
treated for 20 min with PIBF or PIBF plus anti-PIBF IgG, were separated on SDS-PAGE, blotted to nitrocellulose membrane, and reacted with anti-
phospho-STAT6 Abs. B, PIBF treatment induces nuclear translocation of STAT6. Nuclear extracts from untreated human PBL, and those treated for 20
min with PIBF or IL-4 were hybridized with radioactive labeled STAT6 binding specific oligonucleotide probes 5-TCGACTTCCCAAGAACAGCA-3
and their reverse complementary pairs. The samples were separated by nondenaturing PAGE and the bands were detected by autoradiography. Supershift
was performed with anti-STAT6 Ab. C, Time-dependence of STAT6 phosphorylation. STAT6 phosphorylation was tested on lysates of lymphocytes
incubated with 200 ng/ml PIBF (b), IL-4 (a), or progesterone (c) for varying periods. D, Concentration dependence of STAT6 activation by PIBF. STAT6
phosphorylation was tested on lysates of lymphocytes incubated for 20 min with different concentrations of PIBF. Western blots were reacted with
anti-phospho-STAT6 (top) or anti-STAT6 Ab (bottom).
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well as untreated lymphocytes were hybridized with labeled
STAT6 binding, specific oligonucleotide probes and their reverse
complementary pairs. PIBF induced nuclear translocation of
STAT6 in lymphocytes. The specificity of the reaction was verified
with a supershift assay. This result is based on anti-STAT6 IgG-
STAT6 forming high molecular mass complexes, which migrate
slower than STAT6 alone.
In the presence of anti-STAT6 IgG, a supershifted complex ap-
peared in the extract of PIBF-treated lymphocytes. This band
was not detectable when the irrelevant anti-NF-B Ab was used
(Fig. 1B).
To investigate the concentration- and time-dependence of PIBF
effects, STAT6 phosphorylation was tested on lysates of lympho-
cytes incubated with different concentrations of PIBF or with 200
ng/ml PIBF for varying periods. Tyrosine phosphorylated STAT6
appeared as early as 1 min after addition of IL-4 (Fig. 1C, a) or
PIBF (Fig. 1C, b) to the cells, whereas a 24-h continuous presence
of progesterone was required for the same effect (Fig. 1C, c). PIBF
in concentrations from 10 ng to 10 g/ml exerted a concentration-
dependent effect on STAT6 phosphorylation (Fig. 1D). Our earlier
data show that during normal pregnancy PIBF concentrations in
urine reach 100–300 ng/ml, serum PIBF levels of the same women
being usually higher. In patients with malignant tumors, PIBF lev-
els are more variable (100–1000 ng/ml in urine). Based on these
data, we chose 200 ng/ml for further treatments as a concentration
relevant to in vivo biological situations.
STAT6-mediated signal transduction is involved in the cytokine
effects of PIBF
To verify the involvement of the STAT6 pathway in the cytokine
effects of PIBF, STAT6 was silenced in PBL with oligonucleotides
interfering with STAT6 mRNA (siRNA). Cells treated with the
same nucleotides in a scrambled, nongenomic order served as con-
trols. The efficiency and specificity of STAT6 depletion was
checked by reacting the lysates of siRNA-treated cells with anti-
STAT6 or anti-STAT4 and anti-STAT2 Abs. Although the effi-
ciency of STAT6 depletion was variable, silencing was in all cases
specific for STAT6. A representative experiment is shown in Fig.
2A. STAT6 knocked down, as well as control lymphocytes, were
incubated with PIBF for 48 h, and IL-10, IFN-, as well as TNF-
concentrations of the culture medium, were determined with a cy-
tometric bead assay. For controlling the effect of possible LPS
contamination in recombinant PIBF, parallel lymphocyte samples
were treated with lysates of E. coli that had undergone the same
purification procedure as the recombinant PIBF.
Compared with the controls, the concentrations of both TNF-
(Fig. 2C) and IFN- (Fig. 2D) were significantly increased in
STAT6-deficient cells treated with 10 g/ml PIBF. PIBF increased
IL-10 production of intact lymphocytes in a concentration-depen-
dent manner. Similar changes were observed in cells treated with
nongenomic sequence oligonucleotides and in STAT6-deficient
cells. In the latter group, PIBF-induced elevation of IL-10 produc-
tion was lower compared with scrambled (SCR) control; however
the difference was not statistically significant (Fig. 2B). A pitfall of
the RNA interference method is that according to recent findings,
nonspecific effects that include both the up-regulation and suppres-
sion of nontargeted genes can be observed (24), which could ac-
count for elevated IL-10 levels in supernatants of cells treated with
the nongenomic sequence. Therefore SCR control might be more
appropriate as a baseline than untreated cells.
PIBF-induced activation of the STAT6 pathway is mediated by
IL-4R
STAT6 signaling is initiated by the engagement of IL-4R. Assum-
ing that PIBF might be a ligand of IL-4R, the STAT6 activating
effect of PIBF was tested in lymphocytes pretreated with blocking
concentrations of anti-IL-4R or anti-IL-13R Ab. The blocking of
the IL-13R had no effect, but the use of a blocking anti-IL-4R mAb
counteracted PIBF-induced STAT6 activation (Fig. 3A). This was,
however, not due to the inhibition of the binding of PIBF to IL-4R
because we could not demonstrate PIBF binding to IL-4R by
ELISA (Fig. 3B), nor did anti-IL-4R treatment prevent PIBF bind-
ing to its own receptor (Fig. 3C). STAT6 phosphorylation by PIBF
was not affected by simultaneous anti-IL-4 treatment (Fig. 3D).
PIBF induces phosphorylation of the IL-4R-associated Jak1
(Fig. 4A), but not that of the -chain-associated Jak3 (Fig. 4B), and
the former effect is inhibited by anti-IL-4R Ab (Fig. 4A).
Both PIBF and IL-4 treatment resulted in activation of SOCS-3,
and blocking of IL-4R abolished the effect (Fig. 5A). IL-12-in-
duced SOCS-1 activation was inhibited by PIBF, and the latter
effect was abolished by blocking IL-4R (Fig. 5B). SOCS-3 inhibits
IL-12 signaling, which explains the finding that IL-12-induced
STAT4 phosphorylation disappeared after PIBF treatment in the
absence, but not in the presence of anti-IL-4R Ab (Fig. 5C).
Treatment of the cells with anti-IL-12 Ab inhibited STAT4 phos-
phorylation, suggesting that the freshly isolated PBL were under
IL-12 effect (Fig. 5D).
FIGURE 2. STAT6 is required for the cytokine effects of PIBF. The
effect of PIBF on cytokine production by STAT6-deficient (siRNA) lym-
phocytes. Intact lymphocytes, those treated with scrambled oligonucleo-
tides, and those after RNA interference were adjusted to 106 cells/ml in
RPMI 1640 with 10% FCS and cultured for 48 h at 37°C, 5% CO2 in a
humidified atmosphere together with 0.2 or 10 g/ml PIBF, or without
PIBF. Cytokines were determined from the supernatants by cytometric
bead array. Lymphocytes were lysed for Western blot analysis. Controls
include intact lymphocytes () and those treated with nongenomic se-
quence oligonucleotides (SCR). E. coli lysate controls were included to
rule out the effect of LPS contamination on cytokine production. These had
no effect on IL-10 and IFN- production, although they induced a slightly
increased TNF- production. The data shown are corrected for E. coli
lysate control. Data are the mean  SEM of nine individual experiments.
Significantly different (, p 0.05) values from controls are shown. A, The
efficiency and specificity of STAT6 depletion by siRNA. Western blots of
lysates from siRNA-treated cells were reacted with anti-STAT6, anti-
STAT4, or anti-STAT2. A representative experiment is shown. B, The
effect of PIBF on IL-10 production. C, The effect of PIBF on TNF-
production. D, The effect of PIBF on IFN- production.
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Functional association of PIBF receptor and IL-4R with PIBF
receptor as a GPI-anchored protein
Our data suggest that the PIBF receptor might form a heterodimer
with IL-4R to activate the STAT6 pathway. Confocal microscopy
analysis of PE anti-IL-4R and FITC PIBF-labeled cells revealed
a cocapping of the two receptors, when PIBF labeling was done at
37°C (Fig. 6A, top panel), whereas PE anti-CD45 and FITC-PIBF
did not colocalize (data not shown). Six cocapping experiments on
PBL from different healthy individuals under the same conditions
gave similar results. Typically cocapping was observed on 18% of
the cells, and 1.7% of lymphocytes reacted with IL-4R-PE only,
whereas the ratio of single FITC PIBF-positive cells was
negligible.
No capping was seen in cells incubated at 4°C with the Abs (Fig.
6A, bottom panel).
Because IL-4R was a requirement for PIBF signaling, we
tested whether PIBF receptor was a GPI-anchored protein. Digest-
ing the putative anchoring region with PI-PLC resulted in a loss of
STAT6 activation by PIBF, whereas the same effect of IL-4 re-
mained unaltered (Fig. 6B).
Discussion
In this study we suggest the existence of a new type of IL-4R, in
which the -chain of the IL-4R is complemented by the GPI-an-
chored PIBF receptor. The treatment of human PBL with low con-
centrations of PIBF results in immediate phosphorylation and nu-
clear translocation of STAT6. STAT6 activation is dependent on
ligation of IL-4R (21). This implies that for activating STAT6,
PIBF needs to interact with IL-4R. Indeed, the STAT6 activating
effect of PIBF was lost after blocking the IL-4R -chain by a
specific Ab. In contrast, we could not demonstrate a direct binding
of PIBF to IL-4R, nor could we prevent PIBF from binding to its
own receptor by anti-IL-4R treatment. The possibility that the
PIBF Ab binds to a region within PIBF that is required for inter-
action with the IL-4R, thus competing for the same site on PIBF,
can be ruled out because in the ELISA we used a polyclonal anti-
PIBF IgG, which recognizes multiple epitopes on the PIBF mol-
ecule. Furthermore, the assay performed in a reverse order (solid
phase bound PIBF reacted with IL-4R, revealed with anti-IL-
4R) gave similarly negative results. Previously we showed (6)
that supernatants from spleen cells activated in the presence of
PIBF produce significantly more IL-4 than those in the absence of
PIBF. The possible scenario in which instead of PIBF, PIBF-in-
duced IL-4 would bind to the IL-4R and phosphorylate STAT6,
can also be excluded. As short as a 1 min incubation with PIBF is
sufficient to induce the phosphorylation of STAT6. This is too
short an interval for gene induction plus the synthesis of IL-4.
Another argument against this concept is that treatment of the cells
with anti-IL-4 Abs did not inhibit, nor even reduce the effect of
PIBF on STAT6 phosphorylation.
The blocking of the IL-13R (which consists of an IL-13 binding
IL-13R -chain (25, 26) and IL-4R) (27) does not exert a similar
effect, suggesting that the IL-4R -chain is needed for the STAT6-
inducing effect of PIBF.
Because PIBF does not directly bind to IL-4R, but STAT6 phos-
phorylation is inhibited by anti-IL-4R Ab, we investigated the ef-
fect of IL-4R block on Jak phosphorylation in PIBF-treated cells.
FIGURE 4. PIBF phosphorylates Jak1, but not Jak3.
A, The effect of PIBF treatment and IL-4R blocking on
phosphorylation of Jak1. Lysates of untreated human
lymphocytes, and those treated for 20 min with PIBF,
IL-4, or PIBF and anti-IL-4R Ab cells, are reacted with
anti-phospho-Jak1 (top) or anti-Jak1 (bottom) Ab. B,
The effect of PIBF treatment on phosphorylation of
Jak3. Lysates of untreated human lymphocytes, and those
treated for 20 min with IL-4 or PIBF, are reacted with
anti-phospho-Jak3 (top) or anti--actin (bottom) Ab.
FIGURE 3. PIBF-induced STAT6 activation is medi-
ated by IL-4R. A, The effect of IL-4R block on PIBF-in-
duced STAT6 phosphorylation. Lysates of untreated hu-
man lymphocytes, and those treated for 20 min with PIBF,
PIBF and anti-IL-4R, or PIBF and anti-IL-13R Ab, are
reacted with anti-phospho-STAT6 (top) or anti-STAT6
(bottom) Ab. B, Binding PIBF to IL-4R ELISA plates
coated with IL-4R were reacted with increasing concen-
trations of PIBF or IL-4, and subsequently with anti-PIBF
and anti-IL-4 Abs, respectively. A representative experi-
ment is shown. C, The blocking of IL-4R does not inhibit
PIBF binding to its receptor. Lymphocytes were incubated
with 2 g/ml FITC-labeled PIBF in the presence of in-
creasing concentrations of unlabeled PIBF or anti-IL-4R
Ab. The percentage of FITC PIBF binding cells was deter-
mined by flow cytometry. A representative experiment is
shown. D, The effect of anti-IL-4 does not affect PIBF-
induced STAT6 phosphorylation. Lysates of untreated hu-
man lymphocytes, and those treated for 20 min with PIBF,
PIBF and anti-IL-4, IL-4, IL-4 plus anti-IL-4, or anti-IL-4
alone are reacted with anti-phospho-STAT6 (top) or anti-
STAT6 (bottom) Ab.
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PIBF-induced Jak1 phosphorylation was inhibited by anti-IL-4R
Ab treatment, whereas the blocking of IL-13R had no effect.
STAT4 was phosphorylated in untreated cells, and this did not
change upon addition of IL-12. In this study we used freshly iso-
lated lymphocytes from healthy individuals, which produce IL-12.
The treatment of the cells with anti-IL-12 Ab abolished STAT4
phosphorylation, thus phosphorylation of STAT4 in untreated
lymphocytes could be due to IL-12 already present in the system.
The STAT4 activating effect of IL-12 was counteracted by PIBF in
the absence, but not in the presence of anti-IL-4R Ab. This implies
that effects of PIBF (both the positive ones on STAT6 and the
negative ones on STAT4) are dependent on the IL-4R -chain.
Ligand binding of IL-4R leads to phosphorylation of Jak1. Jak
then phosphorylates STATs, which move into the nucleus and ac-
tivate the transcription of, among others, genes coding for the
SOCS proteins. IL-12/STAT4 and IL-4/STAT6 pathways are un-
der negative feedback regulation by SOCS proteins. SOCS-3 is
induced by IL-4 signal, then it binds to IL-12R and inhibits IL-12
signaling (28). Thus, IL-12-induced STAT4 activation is inhibited
in Th2 cells that express high levels of SOCS-3, whereas IL-4/
STAT6 signaling is constitutively activated in Th2 cells, but not in
Th1 cells, with high SOCS-1 expression (16). In our hands, similar
to IL-4, PIBF treatment induced SOCS-3 activation, whereas the
IL-12-induced SOCS-1 expression disappeared after PIBF or IL-4
FIGURE 6. The PIBF receptor is a GPI-anchored
protein and forms a heterodimer with IL-4R. A, Colo-
calization at 4°C (bottom) and cocapping at 37°C (top)
of IL-4R and PIBF receptor. View of FITC PIBF (a),
PE anti-IL-4R (b), and merged (c) are presented. For
capping (top), lymphocytes were incubated with FITC-
conjugated PIBF for 30 min at 37°C, fixed and reacted
with monoclonal anti-IL-4R for 45 min at room tem-
perature, followed by incubation with PE-labeled rat anti-
mouse IgG2A and IgG2B or PE-labeled rat anti-mouse
IgG1 for 30 min at room temperature. Fluorescence and
transmission views are merged to show the cellular lo-
calization of the receptors. B, PI-PLC treatment results
in a loss of STAT6 activation by PIBF. Cell lysates of
PI-PLC digested PIBF, IL-4-treated and control un-
treated (marked as 0) as well as nondigested cells are
reacted with anti-phospho-STAT6 (top) or anti-STAT6
(bottom) Ab.
FIGURE 5. PIBF induces SOCS-3 and inhibits SOCS-1 induction as well as STAT4 phosphorylation via IL-4R. A, The effect of PIBF and anti-IL-4R
Ab on SOCS-3 induction. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF, IL-4, PIBF and anti-IL-4R, IL-4 and
anti-IL-4R, or IL-12, are reacted with anti-SOCS-3 (top) or anti--actin (bottom) Ab. B, The effect of PIBF and anti-IL-4R Ab on IL-12-induced SOCS-1
induction. Lysates of untreated human lymphocytes, and those treated for 20 min with IL-12, IL-12 and PIBF, IL-12 and IL-4, IL-12 and PIBF and
anti-IL-4R, IL-12 and PIBF and anti-IL-13R, or IL-12 and IL-4 and anti-IL-4R Ab are reacted with anti-SOCS-1 (top) or anti--actin (bottom) Ab. C,
The effect of PIBF and anti-IL-4R Ab on STAT4 phosphorylation. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF,
IL-12, IL-12 and PIBF, IL-12 and PIBF and anti-IL-4R, or anti-IL-4R Ab, are reacted with anti-phospho-STAT4 (top) or anti-STAT4 (bottom) Ab. D,
The effect of anti-IL-12 Ab treatment on STAT4 phosphorylation in freshly isolated PBL. Lysates of untreated human PBL, and those treated for 20 min
with anti-IL-12 or IL-12, are reacted with anti-phospho-STAT4 (top) or anti-STAT4 (bottom) Ab.
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treatment. All of the described effects were abolished by the IL-4R
block.
Based on the currently available data, STAT6 signaling is ini-
tiated by IL-4 or IL-13 binding to IL-4R (29). Although we could
not demonstrate direct binding of PIBF to IL-4R, blocking of the
latter suspended all IL-4R-dependent effects of PIBF. Furthermore,
with confocal microscopy we demonstrated not only colocaliza-
tion, but under appropriate conditions, also cocapping of IL-4R
and the PIBF receptor. Therefore the hypothesis was put forward
that, following ligation, the PIBF receptor might either form a
heterodimer with the -chain of the IL-4R, or the engaged PIBF
receptor associates with the complete IL-4R, allowing PIBF to
activate the STAT6 pathway. To date because of the lack of a PIBF
receptor-specific Ab, coprecipitation of the two receptors has not
been performed. However, the finding that PIBF treatment induces
the phosphorylation of Jak1 (associated with the IL-4R -chain),
but not that of Jak3, which is associated with the -chain, provides
strong indirect evidence for the former and against the latter
concept.
Our findings raise the question, why IL-4R is needed for PIBF
signaling. A plausible explanation would be that the PIBF receptor
itself does not possess an intracellular domain; therefore it uses
that of IL-4R. Several proteins are anchored to membranes via a
posttranslational lipid modification, the GPI anchor. Ligation of
these proteins by Abs results in signal transduction, despite the fact
that these molecules have no transmembrane or intracellular do-
mains. Their signaling capacity is due to the association of these
molecules with putative transmembrane proteins that can signal
via conventional mechanisms (30).
Testing the hypothesis that the PIBF receptor was a GPI-an-
chored protein, we digested the anchoring region with PI-PLC.
After this treatment, IL-4 was still able to activate STAT6, but
PIBF failed to do so, suggesting that a GPI-anchored protein was
involved in PIBF signaling. GPI deficiency causes female infertil-
ity in mice (31), but to date the protein needed for maintaining
pregnancy has not been identified. PIBF deficiency ablates murine
pregnancy (5), suggesting that the PIBF receptor might be consid-
ered a candidate. These findings would explain not only the preg-
nancy protective (5), but also the cytokine-promoting (6) and pos-
sible tumor-promoting (2) effects of PIBF.
The concept that both IL-4R and PIBF receptor are required
for PIBF signaling is supported by the following: 1) anti-IL-4R
does not prevent binding of PIBF to its receptor, suggesting that
PIBF receptor and IL-4R are separate entities; 2) digesting the
GPI anchor abolishes PIBF-driven signaling, thus a GPI-anchored
protein is required for PIBF signaling; and 3) anti-IL-4R Ab in-
hibits PIBF-induced STAT6 phosphorylation in intact cells show-
ing that PIBF cannot signal via its own receptor without the in-
volvement of IL-4R. Taken together, the GPI-anchored PIBF
receptor is required, but not sufficient, for PIBF signaling.
Our data suggest the existence of a novel IL-4R (Fig. 7A) in
which upon ligation, the PIBF receptor combines with IL-4R
(Fig. 7B) and induces Jak1 phosphorylation, which in turn, acti-
vates STAT6. In STAT6-deficient cells, both the Th2 cytokine-
inducing and Th1 cytokine-inhibiting effects of PIBF were re-
duced. PIBF-induced SOCS-3, through binding to the IL-12R,
inhibits STAT4 phosphorylation (Fig. 7C) and Th1 responses.
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